Next Article in Journal
Design and Synthesis of New Modified Flexible Purine Bases as Potential Inhibitors of Human PNP
Next Article in Special Issue
Anticancer Properties of 3-Dietoxyphosphorylfuroquinoline-4,9-dione
Previous Article in Journal
Reduced Graphene Oxide-Zinc Sulfide Nanocomposite Decorated with Silver Nanoparticles for Wastewater Treatment by Adsorption, Photocatalysis and Antimicrobial Action
Previous Article in Special Issue
Synthesis of Dihydropyrimidines: Isosteres of Nifedipine and Evaluation of Their Calcium Channel Blocking Efficiency
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 3
10.3390/molecules28030921
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

New Bicyclic Pyridine-Based Hybrids Linked to the 1,2,3-Triazole Unit: Synthesis via Click Reaction and Evaluation of Neurotropic Activity and Molecular Docking

by
Samvel N. Sirakanyan
1,*,
Domenico Spinelli
2,*,
Anthi Petrou
3,
Athina Geronikaki
3,
Victor G. Kartsev
4,
Elmira K. Hakobyan
1,
Hasmik A. Yegoryan
1,
Luca Zuppiroli
5,
Riccardo Zuppiroli
5,
Armen G. Ayvazyan
6,
Ruzanna G. Paronikyan
1,
Tatevik A. Arakelyan
1 and
Anush A. Hovakimyan
1
1
Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L.Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia
2
Dipartimento di Chimica G. Ciamician, Alma Mater Studiorum-Università di Bologna, Via F. Selmi 2, 40126 Bologna, Italy
3
School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
4
InterBioScreen, 119019 Moscow, Russia
5
Department of Industrial Chemistry ‘Toso Montanari’, Alma Mater Studiorum-Università di Bologna, Viale del Risorgimento 4, 40136 Bologna, Italy
6
Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Molecule Structure Research Centre, Ave. Azatutyan 26, Yerevan 0014, Armenia
*
Authors to whom correspondence should be addressed.
Molecules 2023, 28(3), 921; https://doi.org/10.3390/molecules28030921
Submission received: 2 December 2022 / Revised: 29 December 2022 / Accepted: 6 January 2023 / Published: 17 January 2023
(This article belongs to the Special Issue Biologically Active Heterocyclic Compounds)
Browse Figures
Review Reports Versions Notes

Abstract

:
The synthesis of new original bicyclic pyridine-based hybrids linked to the 1,2,3-triazole unit was described via a click reaction. The anticonvulsant activity and some psychotropic properties of the new compounds were evaluated. The biological assays demonstrated that some of the studied compounds showed high anticonvulsant and psychotropic properties. The five most active compounds (7a, d, g, j, and m) contain a pyrano [3,4-c]pyridine cycle with a methyl group in the pyridine ring in their structures. Furthermore, molecular docking studies were performed, and their results are in agreement with experimental data.

1. Introduction

According to the WHO, more than 50 million people worldwide suffer from epilepsy [1]. Epilepsy is one of the most severe diseases of the nervous system, leading to serious complications and consequences in the form of reduced ability to work, social maladaptation, disability, and even premature death in patients [2]. As a result, the treatment of epilepsy appears to be a very important social and socio-economic problem. The primary tasks of the current stage of the treatment of epilepsy and epileptic syndromes are: the widespread introduction of new antiepileptic drugs with innovative mechanisms of action on the “target” of the pathological epileptic system; the use of new drugs not only as an additional therapy for drug-resistant epilepsy, but, perhaps, a faster transition to new forms of drugs at the earliest stages of ineffective treatment with basic drugs [3]. In recent years, with the use of antiepileptic drugs, mainly of the second generation, there has been a tendency to optimize results, aimed at the use of anticonvulsants with extended combined properties [4]. Hence, epileptic mood disorders, twilight clouding of consciousness, epileptic psychoses, epileptic personality changes, and emotional disturbances are known. A new treatment approach allows such drugs to be used in various related areas of neurology and psychiatry when it becomes necessary to alleviate emotional stress, induce sedation, stabilize or prevent mood swings in bipolar disorders of manic-depressive states [5].
Hybridization of bioactive natural and non-natural compounds is one of the most promising and fundamentally novel approaches for the design of new lead structures and the discovery of novel and potent drugs in medicinal chemistry [6,7,8,9,10,11,12,13]. According to biological tests, hybrid molecules, which are generally synthetic compounds, are built of two or more natural or synthetically derived fragments that are linked by at least one carbon-carbon bond and are, in many cases, more active than their respective parent compounds [6,7,8,9,10,11].
In our previous work we demonstrated that the terminal triple bond was obtained based on the 3(6)-hydroxy derivatives of bicyclic pyridines 1, and the compound was found to have strong antiplatelet and vasodilatory potential, as well as an IC50 twice as low as that of the clinically used acetylsalicylic acid [14]. The azido group was synthesized based on the 6-piperazino derivatives of pyrano [3,4-c]pyridines, which show pronounced neurotropic [15,16] and antimicrobial [17] activities. On the other hand, the obtained hybrids contain a 1,2,3-triazole ring, whose derivative can show a wide spectrum of biological properties [18,19,20].
Taking into account the above-mentioned results, herein we describe the synthesis of new original hybrid compounds as potential biologically active substances while studying their neurotropic properties. The click chemistry [21,22,23,24] was used to synthesize the corresponding terminal triple bond and azido group based on the biologically active bicyclic pyridine derivatives.

2. Results and Discussion

2.1. Chemistry

We synthesized terminal alkines from the 3(6)-hydroxy derivatives of cyclopenta[c]pyridine 1a [25], 5,6,7,8-tetrahydroisoquinolines 1b–d [25], pyrano [3,4-c]pyridines 1e–g [14,26], and 2,7-naphtyridines 1h,i [27] to obtain the aimed hybrids, the 1,2,3-triazoles. It should be mentioned that tautomerism is possible in compound 1 lactam-lactim (NH/OH) via proton-migration of a hydrogen atom between the two basic centers. However, the spectroscopic data (IR, NMR spectra, and X-ray data) strongly evidenced that pyrano [3,4-c]pyridines 1 in the crystalline state and in solution exist only in the lactam (NH) tautomeric form [26]. Interestingly, in alkaline solution the situation changes, where by the alkylation of condensed pyridines 1 in basic conditions we obtained high yields of O-alkylated derivatives [24,28]. The same situation was observed during the reaction of compound 1 with propargyl bromide. As a result, relevant O-alkylated derivatives 2a–i [24] were obtained under basic conditions at room temperature in high yields (Scheme 1, Table 1).
However, in an accurate examination of the crude reaction mixture by 1H NMR spectroscopy, we have detected the traces of N-alkylated compounds 3 in ratios of 3–10% with the corresponding 2, which completely disappeared after the recrystallization of the mixture from ethanol.
In the case of compound 3f, we succeeded in isolating and identifying it in its pure state from the reaction mixture with the corresponding compound 2f, due to its different solubility in the ethanol. The structures of compounds 2a–i and 3f were confirmed by IR, NMR, X-ray spectroscopy, and elemental analysis (see Supplementary Material).
Compounds 2f and 3f showed different physico-chemical data. For example, in the 1H NMR spectra, the doublet signal of the OCH2 group in 2f was displayed at 5.06 ppm, while in isomeric 3f the doublet signal of the NCH2 group was shifted up-field to 4.88 ppm. The remaining signals from the protons showed only slight differences. In the IR spectra of compound 3f, the absorption band characteristic for the carbonyl group at 1633 cm–1 was also observed, while for compounds 2a–i it was absent. It was also interesting to compare the X-ray data of compounds 2f and 3f. Crystallographic and experimental data for isomer compounds 2f and 3f are listed in Table 2.
The molecular structure of the compound 3f is shown in Figure 1. Conformational calculations of cyclic fragments showed that the pyridine ring is perfectly planar, with the maximum deviations of atoms from the mean-squared plane not exceeding 0.0284(1) Å. The tetrahydro-1H-pyran ring shows well-expressed “half-chair” conformation. The four atoms (C5, C6, C19, and C20) of the ring lie in the same plane (the maximal shift from plane was 0.0202(1) Å) while atoms O1 and C2 are out of plane with shifts from “half-chair” plane of −0.3172(1) Å and 0.4097(1) Å, respectively. In 3D packing, the intermolecular interactions could be described mainly via van der Waals forces.
The structure of 2f depicted in Figure 1 appears to be similar to that of 3f, with the difference that the prop-1-yne group is linked to an oxygen (O11) atom at the pyridine ring (Figure 1). All bond lengths and angles in the molecules are in good agreement with each other and with their average statistical values. In this structure, the pyridine ring additionally has a planar conformation, with the maximum deviation of atoms from the mean-squared plane not exceeding 0.0144(4) Å. The tetrahydro-1H-pyran ring also shows “half-chair” conformation. The atoms C5, C6, C19, and C20 are located in the same plane (the maximal shift from plane was 0.0079(4) Å). In contrast atoms O1 and C2 are out of the “half-chair” plane showing maximal shifts of 0.3044(4) Å and −0.4616(4)Å, respectively. In 3D packaging, intermolecular interactions are mainly due to van der Waals forces.
In order to obtain the second component, namely azides, we started with 6-piperazino derivatives of pyrano [3,4-c]pyridines 4a–c [15]. Thus, by acylation of compound 4 with chloroacetyl chloride, the relevant 1(8)-alkyl-3(6)-[4-(chloroacetyl)piperazin-1-yl]pyridine-4(5)-carbonitriles 5a–c [24] were obtained. Further reaction of compound 5 with sodium azide in acetone led to the formation of 1(8)-alkyl-3(6)-[4-(azidoacetyl)piperazin-1-yl][c]pyridine-4(5)-carbonitriles 6a–c [24] in high yields (Scheme 2).
The synthesis of new bioactive hybrids was carried out according to the proposed general Scheme 3 via reactions between the propargylated compounds 2 and azido derivatives 6 under the Cu-catalyzed azide-alkyne click reaction [24]. In the majority of the reactions, the hybrids 7a–u were obtained in high yields (Y = 72–87%; Table 3). Their structures were confirmed by IR, NMR, MS spectroscopy, and elemental analysis (see Supplementary Material).
In the 1H NMR spectra of compounds 7a–u the protons of the CH group of the 1,2,3-triazole ring were observed at 7.93–8.01 ppm, while the signals of C≡CH group were absent. The 13C NMR and MS spectra also confirmed their structure.

2.2. Biological Evaluation

The study of the neurotropic activity of 21 newly synthesized heterocyclic compounds (hybrids 7a–u) was carried out according to indicators characterizing anticonvulsant, sedative, and anti-anxiety activity and side effects.
The study of the anticonvulsant activity of hybrids 7a–u was assessed by evaluating the antagonism to pentylenetetrazole (PTZ), thiosemicarbazide convulsive seizures, and maximal electroshock-induced seizures (MES) [29,30,31,32,33]. The PTZ-induced test is considered an experimental model for the clonic component of epilepsy seizures and the prognostic anxiolytic activity of the compounds. PTZ is a common convulsive agent used in animal models to investigate the mechanisms of seizures. The model of thiosemicarbazide (TSC) seizures (affecting the exchange of GABA) causes clonic seizures similar to pentylenetetrazole ones. The MES test is used as an animal model for the generalization of tonic seizures in epilepsy [34,35]. The neurotoxicity and side effects of the compounds (movement coordination disorder, myorelaxation, and ataxia) were also studied on mice with the “rotating rod”[29] test.
To determine the 50% effective (ED50, causing the anticonvulsant effect in 50% of animals, calculated by the test of antagonism to PTZ), 50% neurotoxic (TD50, causing myorelaxation effect in 50% of animals, calculated by the “rotating rod” test), and 50% lethal (LD50, causing death in 50% of animals) doses, a statistical method of probit analysis proposed by Litchfield and Wilcoxon [36] was used. From a practical point of view, the active compounds’ therapeutic (TI = LD50/ED50) indexes were identified. The well-known antiepileptic drug ethosuximide and the tranquilizer diazepam were used as reference drugs [37].
The evaluation of the anticonvulsant activity of all the synthesized hybrid compounds revealed that they, to varying degrees, exhibit pentylentetrazole antagonism. The anti-PTZ activity of the investigated compounds ranges from 20 to 80%. It was found that the studied compounds are superior to ethosuximide in anticonvulsant activity by antagonism to pentylenetetrazole but inferior to diazepam (Table 4, Figure 2). However, unlike diazepam, they do not induce muscle relaxation in the studied doses 50, 200, and 500 mg/kg. They are low-toxic; their acute daily toxicity is in the range of over 650–930 mg/kg, and their therapeutic (TI) indexes are much greater than those of the reference drug ethosuximide (Table 4, Figure 2). Among all, compounds 7a, d, g, j, m, and o have the highest therapeutic indexes. The order of activity of tested compounds toward the PTZ test can be presented as follows: 7m > 7d > 7g > 7a > 7j > 7r = 7n > 7h > 7o = 7f > 7t > 7u > 7i > 7c > 7q. The first five most active hybrids in their structure contain a pyrano [3,4-c]pyridine cycle with a methyl group in the 8 position of the pyridine ring.
Further, the 15 most active hybrids (7a, c, d, f–j, m–o, q, r, t, and u) were selected to be studied on the model of thiosemicarbazide (TSC) seizures (Table 4). The compounds at the dose of 100 mg/kg increased the latency of thiosemicarbazide seizures by 1.5–4.37 times compared to the control. Ethosuximide has approximately the same effect as increasing the latent time of TSC convulsions. Diazepam is not effective in this model. The most active compounds in this test appeared to be 7u and 7t, while the least active was 7h.
The data on the anticonvulsant activity of 15 active compounds in the MES test in comparison with the reference drugs ethosuximide and diazepam in mice are presented in Table 4. According to the MES test, the compounds studied as well as the reference drugs did not exhibit an anticonvulsant effect since they did not protect from tonic and clonic seizures caused by MES.
Next, these compounds (7a, c, d, f–j, m–o, q, r, t, and u) were studied on the “open field” [38,39], “elevated plus maze” (EPM) [40,41], “forced swimming” [42] tests at a dose of 50 mg/kg, since the ED50 of these compounds is within 50 mg/kg at the confidence intervals. For the most active compounds, the conditioned response of passive avoidance (CRPA) test was used to identify learning and memory processes [29,43]. This trend is due to the fact that many of the well-known anticonvulsants, while causing a therapeutic effect, grossly disrupt thought processes, reduce the intellectual abilities of a person, make memorization difficult, and cause amnesia.
The results of the activity of compounds and reference drugs in the “open field” model in rats are shown in Table 5 and Figure 3. As can be seen from the table, the studied compounds statistically significantly increase the number of horizontal and, in some cases, vertical movements. This indicates the activating effect of the compounds. Diazepam showed an activating effect too, in contrast to ethosuximide, which has neither an activating nor a sedative effect at the studied dose. Most of the considered compounds, like diazepam, increase the number of cells examined. The data obtained indicate the anxiolytic (anti-anxiety) activity of the compounds, which is especially pronounced in compounds 7a, g, m, j, and o. Diazepam at a dose of 2 mg/kg has the same properties, in contrast to ethosuximide. The order of activity of tested compounds in this model is: 7m > 7g > 7j > 7a = 7o. The most active compounds were the top five of the previous test. It should be noted that compound 7o, containing two pyrano [3,4-c]pyridine rings, has almost the same activity as that of compound 7a.
In the elevated plus-maze (EPM) model, control animals are predominantly located in closed arms (Table 6, Figure 4). All compounds as well as ethosuximide and diazepam increased, in a statistically significant manner, the time spent by experimental animals in the center. Statistically, the investigated compounds significantly reduce the residence time in the closed arms and the number of entries into the closed arms. After the administration of all compounds, the experimental animals, in contrast to the control animals and those who received ethosuximide at a dose of 200 mg/kg, enter the open arms and stay there for 6.6 (compound 7g) to 66.4 (compound 7m) sec. The administration of these compounds, as well as diazepam, in fact leads to the identification of an anxiolytic effect. In this test again, the most active compound was found to be 7m, followed by 7i.
The forced swimming test (FST) is used to monitor depressive-like behavior and is based on the assumption that immobility reflects a measure of behavioral despair. On the “forced swimming” model, some of the selected compounds (7a, c, g, h, j, m, o, and q) increase the active swimming time and the latent period of the first immobilization (Table 7, Figure 5). In control mice, the first immobilization occurs after 52 s. This indicates that the studied compounds at a dose of 50 mg/kg exhibit some antidepressant effect. The data regarding ethosuximide at a dose of 200 mg/kg are comparable with the control data. The reference drug diazepam at a dose of 2 mg/kg acts similarly to the noted compounds, increasing the latent time of the first immobilization. At the same time, diazepam significantly reduces the total immobilization time, while the compounds 7a, c, g, h, j, m, o, q, and ethosuximide increase this time.
On the model of electroshock retrograde amnesia—conditioned response of passive avoidance (CRPA) (Table 8) within 6 min, control rats on the 1st and 2nd days of the experiment remained in the light compartment for almost the entire period (280.0 s). Under conditions of retrograde amnesia in rats, the administration of compounds at a dose of 50 mg/kg a day, except for compound 7j, causes some increase in the time of reproduction of the reflex in animals. Statistically, these values are significantly different from the control values and indicate the antiamnesic effect of the compounds. Similar data were obtained for the nootropic drug piracetam, in contrast to diazepam, which did not have an antiamnestic effect (diazepam under the same conditions even leads to a decrease in behavioral parameters compared to the control, as well as the compound 7j) (Table 8, Figure 6).

2.3. Molecular Docking

2.3.1. Docking Studies for Prediction of the Mechanism of Anticonvulsant and Anxiolytic Activity (Docking to GABAA Receptor)

It is widely known that antiepileptic drugs target GABAA receptors in order to block sodium channels or enhance γ-aminobutyric acid (GABA) function [44,45]. Therefore, docking studies of all tested compounds were performed in order to get a better understanding of the GABAA receptor inhibitory potency at the molecular level and shed light on the interactions in the active site of the GABAA receptor.
For docking studies, the crystal structure of the GABAA receptor was retrieved from the protein data bank (PDB) with PDB ID: 4COF obtained via X-ray method [46]. The X-ray diffraction structure of the GABAA receptor had a resolution of 2.97 Å, an R value of 0.206, and an R free value of 0.226. As a first step in docking studies and for the validation of docking parameters, the initial co-crystal ligand benzamidine was extracted and re-docked at the catalytic site of a protein using the same parameters and preparation steps as used for the tested compounds. The root-mean-square deviation (RMSD) between co-crystal and re-docked poses was found to be 0.34 Å (Figure 7).
Docking results presented in Table 9 revealed that compound 7j bound tightly in the active site of the GABAA receptor with a value of free binding energy of −10.36 kcal/mol, forming three hydrogen bonds between the nitrogen atoms and residues Tyr97 (N···H, 3.31Å), Thr202 (N···H, 3.13Å) and Tyr205 (N···H, 2.95Å), while diazepam forms only one hydrogen bond with Thr202 (N···H, 2.67Å, Figure 8 and Figure 9). Furthermore, the furan moiety of the compound showed hydrophobic interactions with the residues Ala201 and Phe200, further stabilizing the complex ligand-enzyme.

2.3.2. Docking to the SERT Transporter and the 5-HT1A Receptor

Antidepressant drugs fall into two main categories: tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) [47]. These drugs inhibit the transport of serotonin into the pre-synaptic neuron by inhibiting the serotonin (5-HT) transporter (SERT). SERT is a trans-membrane protein located in the membrane of pre-synaptic neurons that removes serotonin from the synaptic cleft, resulting in the termination of serotonergic neurotransmission. The increase in serotonin activates the 5-HT1A receptors, decreasing the serotonergic neurotransmission and causing a delay in the onset of antidepressant action [48,49]. This delay lasts until HT1A receptors become desensitized and the release of serotonin is normalized.
Taking all the above into account, in order to study if the tested compounds act as dual inhibitors of serotonin transporter (SERT) and alongside antagonize the pre-synaptic auto inhibitory 5-HT1A receptors, we proceeded with docking studies in SERT transporter and 5-HT1A receptor.
As there is no available crystal structure of the SERT transporter in the protein data nank (PDB) we used the x-ray crystal structure of LeuT bound to L-Tryptophan (PDB code: 3F3A), a prokaryotic homologue of SERT [50]. The results of docking studies on the SERT transporter are presented in Table 10.
As a first step in docking studies and for the validation of docking parameters, the initial co-crystal ligand L-Tryptophan was extracted and re-docked at the binding site of the protein using the same parameters and preparation steps as used for the tested compounds. The RMSD between co-crystal and re-docked poses was found to be 0.86 Å (Figure 10).
Compound 7a showed the best docking score, forming two hydrogen bonds. The first one was between the nitrogen atom of the CN group and the hydrogen atom of the side chain of Lys443 (distance 2.42 Å). The second was between the nitrogen atom of the thiazole ring of the compound and the hydrogen of the side chain of Arg11 (distance 2.53 Å) (Figure 11). The docking results coincide with the experimental data.
For docking to the 5-HT1A receptor, the crystal structure of the human β2-adrenergic receptor in complex with the neutral antagonist alprenolol (PDB code: 3NYA) was used [51,52]. For the validation of docking parameters, the initial co-crystal ligand alprenolol was re-docked at the catalytic site of protein, and the root-mean-square deviation (RMSD) between the co-crystal and the re-docked pose was found to be 0.98 Å (Figure 12).
All the tested compounds were docked into the orthosteric binding site of the 5-HT1A receptor (Table 11), and the best docking score was found for compound 7a (−11.23 kcal/mol), which formed five hydrogen bonds with the residues Tyr118, Tyr199, Ser204, Asn312, and Tyr316. Additionally, hydrophobic interactions were observed between methyl substituents of the compound and residues Trp109, Ile309, Tyr308, Phe193, Val114, Tyr110, Ile201, Val297, and Ala200 (Figure 13A). It is worth noting that alprenolol forms hydrogen bonds with the same Tyr316 and Asn312 residues as compound 7a does. Moreover, this compound is oriented in the same cavity of the enzyme as alprenolol (Figure 13B). This may justify the high activity of compound 7a. Finally, the docking studies revealed that this compound can probably be a dual target molecule since it seems to be a good inhibitor of the SERT transporter and a good 5-HT1A receptor binder.

2.4. Drug Likeness

All tested compounds were evaluated for their absorption, distribution profile, and drug-likeness model score (a combined effect of physico-chemical properties, pharmacokinetics, and pharmacodynamics of a compound represented by a numerical value) was computed by MolSoft, (MolSoft, 2007)) and the results are presented in Table 12. As depicted in Figure 9, those with green coloring indicate non drug-like behavior, while those with blue coloring are considered drug-like. Compounds having a zero or negative value cannot be considered drug-like. The drug-likeness score was found to be from 0.33 to 0.83 for all compounds, thus they can be treated as drug candidates (Figure 14).
The ADMET structure-activity relationship server, admetSAR [2], used for this prediction, gives a probability for each ADMET descriptor. More than 40 high predictive models were implemented in admetSAR, which were trained by state-of-the-art machine learning methods. According to prediction, all the tested molecules were able to pass the blood-brain barrier (BBB). We further looked into the possibility of our compounds being P-glycoprotein substrates or inhibitors, which play a critical role in pharmacokinetic properties, particularly distribution and excretion (Table 12). The admetSAR server revealed that all compounds are both good P-glycoprotein substrates (65–73%) and inhibitors (74–78%).

3. Materials and Methods

3.1. Chemistry

3.1.1. General Information

1H and 13C NMR spectra were recorded in DMSO-d6/CCl4 (1/3) solution (300 MHz for 1H and 75 MHz for 13C, respectively) on a Mercury 300VX spectrometer (Varian Inc., Palo Alto, CA, USA). Chemical shifts were reported as δ (parts per million) relative to TMS as internal standard. The IR spectra were recorded on a Nicolet Avatar 330-FT-IR spectrophotometer (Thermo Nicolet, CA, USA) in vaseline, νmax in cm–1. MS spectra were recorded on the Waters Xevo Q-Tof. Melting points were determined on a MP450 melting point apparatus. Elemental analyses were performed on an Elemental Analyzer Euro EA 3000. Crystallographic and experimental data are listed in Table 2. Deposition number 2201666 (for compound 2f) and 1937036 (for compound 3f) contain the supplementary crystallographic data for this paper. The full crystallographic data in CIF format is available free of charge via the internet at: www.ccdc.cam.ac.uk/structures (accessed on 22 December 2022). The unit cell parameters of the crystals of the compounds 2f and 3f were measured on an Enraf-Nonius automated diffractometer CAD-4 at room temperature using the diffraction angles of 24 reflections. The diffraction experiment was performed on the same diffractometer using graphite monochromated MoKα-radiation and a θ/2θ-scan measurement method. The structures were solved by the direct method and refined using the software package SHELXTL [53]. All non-hydrogen atoms were refined in anisotropic approximation by full-matrix least squares methods. The hydrogen atoms were positioned geometrically and refined using a riding model. Compounds 2a, c, e [24]; 5b, c [24]; 6b, c [24]; and 7b, h, o [24] were already described.

3.1.2. General Procedure for the Synthesis of Propargylated Derivatives 2b, d, f, g–I, and 3f

To a stirred suspension of compound 1 (5 mmol) and potassium carbonate (1.4 g, 10 mmol) in absolute DMF (25 mL), the propargyl bromide (0.42 mL, 5.5 mmol) was added in a dropwise manner. The reaction mixture was maintained at room temperature for 5 h. After water was added (50 mL), the resulting crystals were filtered off, washed with water, dried, and recrystallized from ethanol (for compound 3f, chloroform was used).
1-Methyl-3-(prop-2-yn-1-yloxy)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (2b). Colorless solid; yield 71%; mp 94–96 °C; IR ν/cm–1: 2128 (C≡CH), 2221 (C≡N), and 3246 (≡CH). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.76–1.89 (m, 4H, 6,7-CH2), 2.41 (s, 3H, CH3), 2.57–2.62 (m, 2H, 8-CH2), 2.84–2.89 (m, 2H, 5-CH2), 2.90 (t, J = 2.4 Hz, 1H, ≡CH), and 5.02 (d, J = 2.4 Hz, 2H, OCH2). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 20.84, 21.80, 21.85, 24.62, 27.82, 53.09, 75.80, 78.01, 92.92, 113.27, 124.16, 152.01, 158.28, and 159.31. Anal. calcd. for C14H14N2O: C 74.31; H 6.24; and N 12.38%. Found: C 74.69; H 6.44; and N 12.64%.
1-(2-Furyl)-3-(prop-2-yn-1-yloxy)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (2d). Cream solid; yield 74%; mp 162–164 °C; IR ν/cm–1: 2121 (C≡CH), 2217 (C≡N), and 3291 (≡CH). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.80–1.90 (m, 4H, 6,7-CH2), 2.91–2.97 (m, 2H, 8-CH2), 2.93 (t, J = 2.4 Hz, 1H, ≡CH), 3.01–3.07 (m, 2H, 5-CH2), 5.08 (d, J = 2.4 Hz, 2H, OCH2), 6.59 (dd, J = 3.4, 1.7 Hz, 1H, 4-CHfur.), 7.19 (dd, J = 3.4, 0.7 Hz, 1H, 3-CHfur.), and 7.70 (dd, J = 1.7, 0.7 Hz, 1H, 5-CHfur.). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 20.59, 21.89, 25.40, 28.48, 53.35, 75.87, 77.93, 93.69, 111.49, 113.24, 114.25, 122.42, 144.10, 146.35, 152.82, 154.23, and 158.87. Anal. calcd. for C17H14N2O2: C 73.37; H 5.07; and N 10.07%. Found: C 73.70; H 5.24; and N 10.29%.
8-Ethyl-3,3-dimethyl-6-(prop-2-yn-1-yloxy)-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (2f). Colorless solid; yield 70%; mp 146–148 °C; IR ν/cm–1: 2191 (C≡CH), 2222 (C≡N), andand 3267 (≡CH). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.28 (s, 6H, C(CH3)2), 1.28 (t, J = 7.4 Hz, 3H, CH2CH3), 2.62 (q, J = 7.4 Hz, 2H, CH2CH3), 2.77 (s, 2H, CH2), 2.94 (t, J = 2.4 Hz, 1H, ≡CH), 4.63 (s, 2H, OCH2), 5.06 (d, J = 2.4 Hz, 2H, OCH2). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 10.82, 25.66, 26.23, 37.70, 53.32, 58.78, 68.93, 75.94, 77.90, 92.99, 112.93, 120.80, 148.94, 159.32, and 160.18. Anal. calcd. for C16H18N2O2: C 71.09; H 6.71; and N 10.36%. Found: C 71.44; H 6.90; and N 10.61%.
3,3-Dimethyl-8-propyl-6-(prop-2-yn-1-yloxy)-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (2g). Colorless solid; yield 76%; mp 152–154 °C; IR ν/cm–1: 2136 (C≡CH), 2220 (C≡N), and 3281 (≡CH). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.00 (t, J = 7.4 Hz, 3H, CH2CH3), 1.27 (s, 6H, C(CH3)2), 1.71–1.84 (m, 2H, CH2CH3), 2.56 (t, J = 7.4 Hz, 2H, CH2C2H5), 2.77 (s, 2H, CH2), 2.93 (t, J = 2.4 Hz, 1H, ≡CH), 4.63 (s, 2H, OCH2), and 5.05 (d, J = 2.4 Hz, 2H, OCH2). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 13.44, 19.97, 25.66, 34.91, 37.72, 53.32, 58.90, 68.93, 75.93, 77.88, 93.09, 112.93, 121.12, 149.04, 158.44, and 160.06. Anal. calcd. for C17H20N2O2: C 71.81; H 7.09; and N 9.85%. Found: C 72.12; H 7.24; and N 10.06%.
1-Azepan-1-yl-7-isopropyl-3-(prop-2-yn-1-yloxy)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile (2h). Yellow solid; yield 72%; mp 95–97 °C; IR ν/cm–1: 2127 (C≡CH), 2207 (C≡N), and 3245 (≡CH). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.08 (d, J = 6.5 Hz, 6H, CH(CH3)2), 1.56–1.64 (m, 4H, C6H12N), 1.79–1.88 (m, 4H, C6H12N), 2.67–2.73 (m, 2H, NCH2CH2), 2.81–2.90 (m, 4H, NCH2CH2, ≡CH, CH(CH3)2), 3.40 (s, 2H, NCH2), 3.57–3.63 (m, 4H, N(CH2)2), and 4.93 (d, J = 2.4 Hz, 2H, OCH2). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 18.09, 26.24, 28.20, 29.13, 44.22, 49.51, 50.82, 52.68, 52.74, 52.80, 53.32, 75.39, 78.46, 82.95, 114.60, 150.66, 158.39, and 159.21. Anal. calcd. for C21H28N4O: C 71.56; H 8.01; and N 15.90%. Found: C 71.92; H 8.20; and N 16.15%.
1-Azepan-1-yl-7-benzyl-3-(prop-2-yn-1-yloxy)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile (2i). Yellow solid; yield 73%; mp 46–48 °C; IR ν/cm–1: 2125 (C≡CH), 2206 (C≡N), and 3248 (≡CH). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.47–1.56 (m, 4H, C6H12N), 1.69–1.78 (m, 4H, C6H12N), 2.67–2.73 (m, 2H, NCH2CH2), 2.85–2.91 (m, 3H, NCH2CH2, ≡CH), 3.34 (s, 2H, NCH2), 3.51–3.57 (m, 4H, N(CH2)2), 3.65 (s, 2H, CH2Ph), 4.93 (d, J = 2.4 Hz, 2H, OCH2), and 7.18–7.30 (m, 5H, Ph). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 18.12, 26.10, 28.06, 28.56, 48.35, 50.73, 52.77, 53.78, 61.75, 75.38, 75.41, 82.81, 110.25, 114.58, 126.58, 127.68, 128.20, 137.42, 150.27, 158.16, and 159.31. Anal. calcd. for C25H28N4O: C 74.97; H 7.05; and N 13.99%. Found: C 75.29; H 7.21; and N 14.22%.
8-Ethyl-3,3-dimethyl-6-oxo-7-(prop-2-yn-1-yloxy)-3,4,6,7-tetrahydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (3f). Colorless solid; yield 10%; mp 163–165 °C; IR ν/cm–1: 1633 (C=O), 2131 (C≡CH), 2223 (C≡N), and 3256 (≡CH). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.28 (s, 6H, C(CH3)2), 1.28 (t, J = 7.5 Hz, 3H, CH2CH3), 2.71 (s, 2H, CH2), 2.77 (q, J = 7.5 Hz, 2H, CH2CH3), 2.89 (t, J = 2.4 Hz, 1H, ≡CH), 4.56 (s, 2H, OCH2), and 4.88 (d, J = 2.5 Hz, 2H, NCH2). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 11.56, 21.87, 25.89, 32.79, 38.38, 58.36, 69.20, 73.89, 77.72, 99.91, 110.22, 114.22, 151.33, 154.74, and 158.28. Anal. calcd. for C16H18N2O2: C 71.09; H 6.71; and N 10.36%. Found: C 71.46; H 6.88; and N 10.62%.

3.1.3. Procedure for the Synthesis of 6-[4-(Chloroacetyl)piperazin-1-yl]-3,3,8-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (5a)

To a stirred solution of compound 4a (1.43 g, 5 mmol) and trimethylamine (0.84 mL, 6 mmol) in benzene (50 mL) the chloroacetyl chloride (4.8 mL, 6 mmol) was added in a dropwise manner. The reaction mixture was maintained at 35 °C for 6 h. Then the reaction mixture was cooled at room temperature, the solvent was removed under vacuum and water (50 mL) was added. The resulting crystals were filtered off, washed with water, dried, and recrystallized from ethanol. Colorless solid; yield 88%; mp 129–130 °C; IR ν/cm–1: 1666 (C=O) and 2207 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.27 (s, 6H, C(CH3)2), 2.30 (s, 3H, CH3), 2.70 (s, 2H, CH2), 3.54–3.71 (m, 8H, C4H8N2), 4.23 (s, 2H, CH2Cl), and 4.56 (s, 2H, OCH2). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 20.97, 25.73, 37.72, 40.80, 41.16, 45.11, 47.56, 48.11, 59.19, 69.04, 93.44, 115.47, 119.52, 147.75, 155.35, 159.11, and 164.23. Anal. calcd. For C18H23ClN4O2: C 59.58; H 6.39; and N 15.44%. Found: C 59.92; H 6.55; and N 15.68%.

3.1.4. Procedure for the Synthesis of 6-[4-(Azidoacetyl)piperazin-1-yl]-3,3,8-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (6a)

A mixture of compound 5a (1.81 g, 5 mmol) and sodium azide (0.65 g, 10 mmol) in acetone (50 mL) was heated at reflux for 15 h. After filtration the solvent was evaporated, and water (50 mL) was added. The resulting crystals were filtered off, washed with water, dried, and recrystallized from ethanol. Colorless solid; yield 86%; mp 130–132 °C; IR ν/cm−1: 1650 (C=O), 2105 (N3), and 2211 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.27 (s, 6H, C(CH3)2), 2.29 (s, 3H, CH3), 2.70 (s, 2H, CH2), 3.48–3.72 (m, 8H, C4H8N2), 4.05 (s, 2H, CH2N3), and 4.56 (s, 2H, OCH2). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 20.99, 25.75, 37.74, 41.04, 43.84, 47.60, 47.97, 49.58, 59.20, 69.06, 93.33, 115.53, 119.48, 147.78, 155.40, 159.11, and 165.36. Anal. calcd. for C18H23N7O2: C 58.52; H 6.28; and N 26.54%. Found: C 58.91; H 6.48; and N 26.81%.

3.1.5. General Procedure for the Synthesis of 1,2,3-Triazoles 7a, c–g, i–n, p–u

Propargyl derivatives of fused pyridines 2 (2 mmol) and corresponding azides 6 (2.2 mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (30 mL). Sodium ascorbate (0.04 g, 0.2 mmol, of freshly prepared solution in water) was added, followed by copper(II) sulfate pentahydrate (0.05 g, 0.2 mmol, in water). The mixture was stirred for 10 h at room temperature and then 10 h at 40–50 °C. After cooling water was added (50 mL), the precipitate was filtered off, washed with water, and recrystallized from a mixture of ethanol-chloroforme (1:3).
6-{4-[(4-{[(4-Cyano-1-isopropyl-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-3,3,8-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7a). Colorless solid; yield 78%; mp 221–223 °C; IR ν/cm–1: 1665 (C=O) and 2216 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.27 (d, J = 6.6 Hz, 6H, CH(CH3)2), 1.28 (s, 6H, C(CH3)2), 2.13–2.24 (m, 2H, 6’-CH2), 2.31 (s, 3H, CH3), 2.71 (s, 2H, 4-CH2), 2.90 (t, J = 7.4 Hz, 2H, 7′-CH2), 3.03 (t, J = 7.6 Hz, 2H, 5’-CH2), 3.05 (sp, J = 6.6 Hz, 1H, CH(CH3)2), 3.58–3.75 (m, 8H, C4H8N2), 4.57 (s, 2H, 1-CH2), 5.48 (s, 2H, NCH2), 5.55 (s, 2H, OCH2), and 7.94 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 20.60, 20.99, 23.89, 25.73, 28.68, 32.00, 32.70, 37.73, 41.21, 43.97, 47.49, 47.94, 50.35, 59.19, 59.64, 69.04, 89.74, 93.24, 113.81, 115.55, 119.42, 125.19, 129.59, 141.79, 147.74, 155.39, 159.08, 161.01, 161.22, 162.61, and 163.78. Anal. calcd. for C33H39N9O3: C 65.01; H 6.45; and N 20.68%. Found: C 65.33; H 6.62; and N 20.91%. ESI + MS: [C33H39N9O3Na1]+ Found: 632.30747.
6-{4-[(4-{[(4-Cyano-1-isopropyl-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-3,3-dimethyl-8-propyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7c). Colorless solid; yield 73%; mp 240–241 °C; IR ν/cm–1: 1656 (C=O) and 2216 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.00 (t, J = 7.4 Hz, 3H, CH2CH3), 1.27 (d, J = 6.7 Hz, 6H, CH(CH3)2), 1.28 (s, 6H, C(CH3)2), 1.67–1.80 (m, 2H, CH2CH3), 2.13–2.24 (m, 2H, 6′-CH2), 2.48–2.54 (m, 2H, CH2C2H5), 2.72 (s, 2H, 4-CH2), 2.90 (t, J = 7.3 Hz, 2H, 7′-CH2), 3.03 (t, J = 7.6 Hz, 2H, 5´-CH2), 3.05 (sp, J = 6.7 Hz, 1H, CH(CH3)2), 3.59–3.76 (m, 8H, C4H8N2), 4.60 (s, 2H, 1-CH2), 5.48 (s, 2H, NCH2), 5.55 (s, 2H, OCH2), and 7.93 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 13.53, 20.01, 20.61, 23.90, 25.74, 28.68, 32.01, 32.70, 35.20, 37.88, 41.20, 43.96, 47.40, 47.97, 50.34, 58.94, 59.66, 68.97, 89.76, 93.18, 113.82, 115.57, 119.08, 125.18, 129.58, 141.79, 147.96, 158.54, 159.06, 161.01, 161.23, 162.61, and 163.77. Anal. calcd. for C35H43N9O3: C 65.91; H 6.80; and N 19.77%. Found: C 66.31; H 7.01; and N 20.05%. ESI + MS: [C35H43N9O3Na1]+ Found: 660.33877.
6-{4-[(4-{[(4-Cyano-1-methyl-5,6,7,8-tetrahydroisoquinolin-3-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-1,3,3-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7d). Cream solid; yield 84%; mp 254–256 °C; IR ν/cm–1: 1669 (C=O), and 2199, 2227 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.28 (s, 6H, C(CH3)2), 1.76–1.88 (m, 4H, 6,7-CH2), 2.31 (s, 3H, 1′-CH3), 2.45 (s, 3H, 1-CH3), 2.57–2.63 (m, 2H, 8-CH2), 2.71 (s, 2H, 5′-CH2), 2.81–2.89 (m, 2H, 5-CH2), 3.58–3.76 (m, 8H, C4H8N2), 4.57 (s, 2H, 8′-CH2), 5.47 (s, 2H, NCH2), 5.52 (s, 2H, OCH2), and 7.96 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 20.84, 20.95, 21.80, 21.91, 24.58, 25.70, 27.78, 37.70, 41.19, 43.94, 47.44, 47.89, 50.32, 59.16, 59.27, 69.01, 92.67, 93.21, 113.62, 115.50, 119.37, 123.71, 125.56, 147.71, 151.90, 155.34, 158.43, 159.04, 160.13, and 163.76. Anal. calcd. for C32H37N9O3: C 64.52; H 6.26; and N 21.16%. Found: 64.88; H 6.74; and N 21.41%.
6-{4-[(4-{[(4-Cyano-1-methyl-5,6,7,8-tetrahydroisoquinolin-3-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-1-ethyl-3,3-dimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7e). Cream solid; yield 71%; mp 214–216 °C; IR ν/cm–1: 1668 (C=O), and 2206, 2225 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.25 (t, J = 7.5 Hz, 3H, CH2CH3), 1.28 (s, 6H, C(CH3)2), 1.75–1.89 (m, 4H, 6,7-CH2), 2.45 (s, 3H, 1-CH3), 2.57 (q, J = 7.5 Hz, 2H, CH2CH3), 2.58–2.63 (m, 2H, 8-CH2), 2.72 (s, 2H, 5′-CH2), 2.82–2.87 (m, 2H, 5-CH2), 3.61–3.76 (m, 8H, C4H8N2), 4.60 (s, 2H, 8′-CH2), 5.48 (s, 2H, NCH2), 5.52 (s, 2H, OCH2), and 7.95 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 10.87, 20.87, 21.84, 21.95, 24.62, 25.74, 26.44, 27.81, 37.86, 41.18, 41.21, 43.95, 47.39, 47.90, 50.34, 58.82, 59.31, 68.97, 92.70, 93.03, 113.65, 115.58, 118.75, 123.74, 125.51, 141.77, 147.85, 151.93, 158.45, 159.12, 159.38, 160.16, and 163.78. Anal. calcd. for C33H39N9O3: 65.01; H 6.45; and N 20.68%. Found: C 65.32; H 6.62; and N 20.90%.
6-{4-[(4-{[(4-Cyano-1-methyl-5,6,7,8-tetrahydroisoquinolin-3-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-3,3-dimethyl-1-propyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7f). Cream solid; yield 75%; mp 182–184 °C; IR ν/cm–1: 1674 (C=O) and 2220 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.00 (t, J = 7.5 Hz, 3H, CH2CH3), 1.28 (s, 6H, C(CH3)2), 1.67–1.89 (m, 6H, 6,7-CH2, CH2CH3), 2.45 (s, 3H, 1-CH3), 2.47–2.54 (m, 2H, CH2C2H5), 2.57–2.63 (m, 2H, 8-CH2), 2.72 (s, 2H, 5′-CH2), 2.80–2.91 (m, 2H, 5-CH2), 3.59–3.76 (m, 8H, C4H8N2), 4.60 (s, 2H, 8′-CH2), 5.47 (s, 2H, NCH2), 5.52 (s, 2H, OCH2), and 7.95 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 13.49, 19.97, 20.85, 21.82, 24.59, 25.71, 27.79, 35.17, 37.85, 41.18, 43.95, 47.38, 47.94, 50.31, 58.91, 59.28, 68.93, 92.68, 93.14, 113.62, 115.53, 119.03, 123.72, 125.51, 125.54, 147.92, 151.91, 152.24, 158.43, 158.50, 158.86, 159.02, 160.14, and 163.74. Anal. calcd. for C34H41N9O3: 65.47; H 6.63; and N 20.21%. Found: C 65.82; H 6.82; and N 20.45%.
6-{4-[(4-{[(4-Cyano-1-isopropyl-5,6,7,8-tetrahydroisoquinolin-3-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-1,3,3-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7g). Colorless solid; yield 81%; mp 225–227 °C; IR ν/cm–1: 1668 (C=O), and 2199, 2227 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.25 (d, J = 6.7 Hz, 6H, CH(CH3)2), 1.28 (s, 6H, C(CH3)2), 1.79–1.86 (m, 4H, 6,7-CH2), 2.31 (s, 3H, 1′-CH3), 2.66–2.73 (m, 2H, 8-CH2), 2.71 (s, 2H, 5′-CH2), 2.84–2.89 (m, 2H, 5-CH2), 3.22 (sp, J = 6.7 Hz, 1H, CH(CH3)2), 3.58–3.75 (m, 8H, C4H8N2), 4.57 (s, 2H, 8′-CH2), 5.48 (s, 2H, NCH2), 5.55 (s, 2H, OCH2), and 7.93 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 20.84, 20.90, 21.0, 21.97, 23.82, 25.74, 28.12, 30.36, 37.74, 41.24, 43.96, 47.49, 47.95, 50.34, 59.19, 69.05, 92.69, 93.26, 113.72, 115.56, 119.43, 122.26, 125.15, 141.85, 147.75, 152.55, 155.40, 159.10, 160.48, 163.80, and 166.06. Anal. calcd. for C34H41N9O3: 65.47; H 6.63; and N 20.21%. Found: C 65.86; H 6.85; and N 20.49%. ESI + MS: [C34H41N9O3Na1]+ Found: 646.32303.
6-{4-[(4-{[(4-Cyano-1-isopropyl-5,6,7,8-tetrahydroisoquinolin-3-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-3,3-dimethyl-1-propyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7i). Cream solid; yield 74%; mp 212–214 °C; IR ν/cm–1: 1656 (C=O) and 2215 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.00 (t, J = 7.3 Hz, 3H, CH2CH3), 1.25 (d, J = 6.7 Hz, 6H, CH(CH3)2), 1.28 (s, 6H, C(CH3)2), 1.67–1.78 (m, 2H, CH2CH3), 1.79–1.87 (m, 4H, 6,7-CH2), 2.48–2.52 (m, 2H, CH2C2H5), 2.66–2.71 (m, 2H, 8-CH2), 2.72 (s, 2H, 5′-CH2), 2.84–2.89 (m, 2H, 5-CH2), 3.22 (sp, J = 6.7 Hz, 1H, CH(CH3)2), 3.59–3.75 (m, 8H, C4H8N2), 4.60 (s, 2H, 8′-CH2), 5.47 (s, 2H, NCH2), 5.55 (s, 2H, OCH2), and 7.93 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 13.51, 19.99, 20.82, 20.88, 21.96, 23.81, 25.72, 28.10, 30.34, 35.18, 37.87, 41.18, 43.94, 47.39, 47.94, 50.32, 58.94, 59.18, 68.95, 92.69, 93.15, 113.69, 115.55, 119.05, 122.22, 125.11, 141.89, 147.94, 152.52, 158.52, 159.04, 160.47, 163.73, and 166.02. Anal. calcd. for C36H45N9O3: 66.34; H 6.96; and N 19.34%. Found: C 66.67; H 7.14; and N 19.59%.
6-(4-{[4-({[4-Cyano-1-(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy}methyl)-1H-1,2,3-triazol-1-yl]acetyl}piperazin-1-yl)-3,3,8-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7j). Cream solid; yield 77%; mp 236–238 °C; IR ν/cm–1: 1662 (C=O) and 2213 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.28 (s, 6H, C(CH3)2), 1.82–1.87 (m, 4H, 6′,7′-CH2), 2.30 (s, 3H, CH3), 2.71 (s, 2H, 4-CH2), 2.90–2.95 (m, 2H, 8´-CH2), 2.99–3.04 (m, 2H, 5´-CH2), 3.57–3.74 (m, 8H, C4H8N2), 4.57 (s, 2H, 1-CH2), 5.47 (s, 2H, NCH2), 5.60 (s, 2H, OCH2), 6.63 (dd, J = 3.5,1.7 Hz, 1H, 4-CHfur.), 7.25 (d, J = 3.5 Hz, 1H, 3-CHfur.), 7.75 (d, J = 1.7 Hz, 1H, 5-CHfur.), and 8.01 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 20.62, 21.00, 21.93, 25.49, 25.74, 28.46, 37.72, 41.21, 43.96, 47.47, 47.48, 47.91, 50.39, 59.20, 59.45, 69.05, 93.22, 93.60, 111.60, 113.63, 114.39, 115.57, 119.41, 122.11, 125.60, 141.77, 144.19, 146.53, 147.74, 152.59, 154.16, 155.40, 159.08, 159.71, and 163.80. Anal. calcd. for C35H37N9O4: C 64.90; H 5.76; and N 19.46%. Found: C 65.27; H 5.97; and N 19.73%. ESI + MS: [C35H37N9O4Na1]+ Found: 670.28664.
6-(4-{[4-({[4-Cyano-1-(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy}methyl)-1H-1,2,3-triazol-1-yl]acetyl}piperazin-1-yl)-1-ethyl-3,3-dimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7k). Cream solid; yield 72%; mp 244–246 °C; IR ν/cm–1: 1672 (C=O), and 2200, 2223 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.25 (t, J = 7.5 Hz, 3H, CH2CH3), 1.27 (s, 6H, C(CH3)2), 1.80–1.88 (m, 4H, 6,7-CH2), 2.56 (q, J = 7.5 Hz, 2H, CH2CH3), 2.71 (s, 2H, 5′-CH2), 2.88–2.95 (m, 2H, 8-CH2), 2.98–3.04 (m, 2H, 5-CH2), 3.60–3.74 (m, 8H, C4H8N2), 4.59 (s, 2H, 8′-CH2), 5.48 (s, 2H, NCH2), 5.59 (s, 2H, OCH2), 6.62 (dd, J = 3.5,1.7 Hz, 1H, 4-CHfur.), 7.25 (d, J = 3.5 Hz, 1H, 3-CHfur.), 7.75 (d, J = 1.7 Hz, 1H, 5-CHfur.), and 8.01 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 10.86, 20.60, 21.91, 25.47, 25.72, 26.43, 28.44, 37.83, 41.19, 43.95, 47.36, 47.87, 50.36, 58.81, 59.44, 68.97, 92.98, 93.59, 111.58, 113.61, 114.37, 115.60, 118.75, 122.10, 125.59, 141.79, 144.16, 146.52, 147.83, 152.58, 154.14, 159.09, 159.38, 159.71, and 163.77. Anal. calcd. for C36H39N9O4: C 65.34; H 5.94; and N 19.05%. Found: C 65.66; H 6.11; and N 19.28%.
6-(4-{[4-({[4-Cyano-1-(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy}methyl)-1H-1,2,3-triazol-1-yl]acetyl}piperazin-1-yl)-3,3-dimethyl-8-propyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7l). Brown solid; yield 79%; mp 144–146 °C; IR ν/cm–1: 1654 (C=O) and 2215 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 0.99 (t, J = 7.4 Hz, 3H, CH2CH3), 1.27 (s, 6H, C(CH3)2), 1.66–1.80 (m, 2H, CH2CH3), 1.81–1.88 (m, 4H, 6′,7′-CH2), 2.43–2.54 (m, 2H, 8´-CH2), 2.72 (s, 2H, 4-CH2), 2.88–2.95 (m, 2H, CH2C2H5), 2.97–3.05 (m, 2H, 5´-CH2), 3.58–3.74 (m, 8H, C4H8N2), 4.60 (s, 2H, 1-CH2), 5.47 (s, 2H, NCH2), 5.60 (s, 2H, OCH2), 6.62 (dd, J = 3.5,1.7 Hz, 1H, 4-CHfur.), 7.25 (d, J = 3.5 Hz, 1H, 3-CHfur.), 7.74 (d, J = 1.7 Hz, 1H, 5-CHfur.), and 8.01 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 13.53, 20.01, 20.63, 21.94, 25.49, 25.73, 28.46, 35.20, 37.87, 41.21, 43.96, 47.41, 47.93, 50.37, 58.94, 59.45, 68.97, 93.14, 93.61, 111.59, 113.62, 114.38, 115.58, 119.06, 122.12, 125.58, 144.17, 146.55, 147.95, 152.60, 154.16, 158.55, 159.04, and 163.78. Anal. calcd. for C37H41N9O4: C 65.76; H 6.12; and N 18.65%. Found: C 66.12; H 6.32; and N 18.90%. ESI + MS: [C37H41N9O4Na1]+ Found: 698.31793.
6-{4-[(4-{[(5-Cyano-3,3,8-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridin-6-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-3,3,8-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7m). Colorless solid; yield 85%; mp 224–226 °C; IR ν/cm–1: 1673 (C=O), and 2210, 2228 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.28 (s, 12H, 2C(CH3)2), 2.30 (s, 3H, CH3), 2.40 (s, 3H, CH3), 2.71 (s, 2H, 4-CH2), 2.75 (s, 2H, 4′-CH2), 3.57–3.75 (m, 8H, C4H8N2), 4.57 (s, 2H, 1-CH2), 4.61 (s, 2H, 1′-CH2), 5.48 (s, 2H, NCH2), 5.54 (s, 2H, OCH2), and 7.98 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 20.81, 21.01, 25.68, 25.74, 37.57, 37.73, 41.22, 43.98, 47.48, 47.94, 50.37, 59.19, 59.52, 69.01, 69.05, 92.96, 93.26, 113.29, 115.57, 119.43, 121.00, 125.70, 141.52, 147.75, 148.74, 155.31, 155.40, 159.09, 160.84, and 163.82. Anal. calcd. for C33H39N9O4: C 63.34; H 6.28; and N 20.15%. Found: C 63.73; H 6.52; and N 20.43%. ESI + MS: [C33H39N9O4Na1]+ Found: 648.30223.
6-{4-[(4-{[(5-Cyano-3,3,8-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridin-6-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-1-ethyl-3,3-dimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7n). Colorless solid; yield 87%; mp 222–224 °C; IR ν/cm–1: 1651 (C=O), and 2205, 2225 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.25 (t, J = 7.5 Hz, 3H, CH2CH3), 1.27 (s, 6H, C(CH3)2), 1.28 (s, 6H, C(CH3)2), 2.40 (s, 3H, CH3), 2.57 (q, J = 7.5 Hz, 2H, CH2CH3), 2.72 (s, 2H, 4-CH2), 2.75 (s, 2H, 4′-CH2), 3.61–3.75 (m, 8H, C4H8N2), 4.60 (s, 2H, 1-CH2), 4.61 (s, 2H, 1′-CH2), 5.48 (s, 2H, NCH2), 5.55 (s, 2H, OCH2), and 7.97 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 10.88, 20.79, 25.68, 25.75, 26.45, 37.57, 37.86, 41.20, 43.92, 43.96, 47.41, 47.91, 50.35, 58.83, 59.18, 59.53, 68.99, 92.98, 93.03, 113.26, 115.61, 118.77, 120.99, 125.68, 141.54, 147.86, 148.73, 155.30, 159.12, 159.39, 160.84, and 163.79. Anal. calcd. for C34H41N9O4: C 63.83; H 6.46; and N 19.70%. Found: C 64.16; H 6.65; and N 19.94%.
6-{4-[(4-{[(5-Cyano-8-ethyl-3,3-dimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridin-6-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-1,3,3-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7p). Colorless solid; yield 78%; mp 239–241 °C; IR ν/cm–1: 1671 (C=O), and 2211, 2224 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.27 (s, 12H, 2C(CH3)2), 1.32 (t, J = 7.5 Hz, 3H, CH2CH3), 2.31 (s, 3H, CH3), 2.65 (q, J = 7.5 Hz, 2H, CH2CH3), 2.71 (s, 2H, 4-CH2), 2.75 (s, 2H, 4′-CH2), 3.58–3.75 (m, 8H, C4H8N2), 4.57 (s, 2H, 1-CH2), 4.64 (s, 2H, 1′-CH2), 5.48 (s, 2H, NCH2), 5.57 (s, 2H, OCH2), and 7.96 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 11.04, 21.0, 25.68, 25.74, 26.36, 37.66, 37.71, 41.21, 43.95, 47.47, 47.50, 47.92, 50.36, 58.82, 59.42, 59.45, 69.05, 92.87, 93.25, 113.32, 115.56, 119.42, 120.37, 125.48, 141.60, 147.76, 148.87, 155.40, 159.08, 159.51, 161.05, and 163.80. Anal. calcd. for C34H41N9O4: C 63.83; H 6.46; and N 19.70%. Found: C 64.21; H 6.68; and N 19.97%.
6-{4-[(4-{[(5-Cyano-8-ethyl-3,3-dimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridin-6-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-8-ethyl-3,3-dimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7q). Colorless solid; yield 83%; mp 217–219 °C; IR ν/cm–1: 1676 (C=O), and 2214, 2234 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.25 (t, J = 7.4 Hz, 3H, CH2CH3), 1.27 (s, 12H, 2C(CH3)2), 1.32 (t, J = 7.4 Hz, 3H, CH2CH3), 2.57 (q, J = 7.4 Hz, 2H, CH2CH3), 2.65 (q, J = 7.4 Hz, 2H, CH2CH3), 2.72 (s, 2H, 4-CH2), 2.76 (s, 2H, 4′-CH2), 3.61–3.75 (m, 8H, C4H8N2), 4.60 (s, 2H, 1-CH2), 4.64 (s, 2H, 1′-CH2), 5.48 (s, 2H, NCH2), 5.57 (s, 2H, OCH2), and 7.96 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 10.88, 11.04, 25.68, 25.75, 26.36, 26.44, 37.70, 37.86, 41.19, 43.95, 47.40, 47.92, 50.35, 58.82, 59.45, 68.95, 68.99, 92.87, 93.03, 113.32, 115.61, 118.78, 120.38, 125.48, 141.60, 147.86, 148.87, 159.13, 159.40, 159.51, 161.06, and 163.79. Anal. calcd. for C35H43N9O4: C 64.30; H 6.63; and N 19.28%. Found: C 64.62; H 6.80; and N 19.51%. ESI + MS: [C35H43N9O4Na1]+ Found: 676.33365.
6-[(1-{2-[4-(5-Cyano-3,3-dimethyl-8-propyl-3,4-dihydro-1H-pyrano [3,4-c]pyridin-6-yl)piperazin-1-yl]-2-oxoethyl}-1H-1,2,3-triazol-4-yl)methoxy]-8-ethyl-3,3-dimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7r). Colorless solid; yield 76%; mp 206–208 °C; IR ν/cm–1: 1679 (C=O), and 2211, 2229 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ1.00 (t, J = 7.3 Hz, 3H, CH2CH2CH3), 1.27 (s, 12H, 2C(CH3)2), 1.32 (t, J = 7.4 Hz, 3H, CH2CH3), 1.67–1.80 (m, 2H, CH2CH2CH3), 2.48–2.54 (m, 2H, CH2C2H5), 2.65 (q, J = 7.4 Hz, 2H, CH2CH3), 2.72 (s, 2H, 4-CH2), 2.76 (s, 2H, 4′-CH2), 3.60–3.76 (m, 8H, C4H8N2), 4.60 (s, 2H, 1-CH2), 4.64 (s, 2H, 1′-CH2), 5.48 (s, 2H, NCH2), 5.57 (s, 2H, OCH2), and 7.96 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 11.04, 13.53, 19.99, 25.68, 25.73, 26.36, 35.20, 37.70, 37.87, 41.20, 43.96, 47.40, 47.95, 47.98, 50.35, 58.81, 58.94, 59.45, 68.94, 68.97, 92.88, 93.17, 113.29, 115.57, 119.08, 120.36, 125.45, 141.59, 147.95, 148.86, 158.53, 159.04, 159.49, 161.04, and 163.77. Anal. calcd. for C36H45N9O4: C 64.75; H 6.79; and N 18.88%. Found: C 65.10; H 6.98; and N 19.14%. ESI + MS: [C36H45N9O4Na1]+ Found: 690.34927.
6-{4-[(4-{[(5-Cyano-3,3-dimethyl-8-propyl-3,4-dihydro-1H-pyrano [3,4-c]pyridin-6-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-3,3,8-trimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7s). Colorless solid; yield 79%; mp 192–194 °C; IR ν/cm–1: 1672 (C=O) and 2213 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ1.03 (t, J = 7.4 Hz, 3H, CH2CH3), 1.27 (s, 6H, C(CH3)2), 1.28 (s, 6H, C(CH3)2), 1.74–1.87 (m, 2H, CH2CH3), 2.31 (s, 3H, CH3), 2.56–2.62 (m, 2H, CH2C2H5), 2.71 (s, 2H, 4-CH2), 2.76 (s, 2H, 4′-CH2), 3.58–3.75 (m, 8H, C4H8N2), 4.57 (s, 2H, 1-CH2), 4.65 (s, 2H, 1′-CH2), 5.48 (s, 2H, NCH2), 5.55 (s, 2H, OCH2), and 7.96 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 13.53, 20.17, 21.00, 25.68, 25.74, 35.07, 37.73, 41.22, 43.98, 47.48, 47.94, 50.37, 58.95, 59.20, 59.50, 68.93, 69.05, 92.94, 93.26, 113.31, 115.57, 119.44, 120.68, 125.44, 141.56, 147.76, 148.96, 155.40, 158.65, 159.09, 160.94, and 163.80. Anal. calcd. for C35H43N9O4: C 64.30; H 6.63; and N 19.28%. Found: C 64.70; H 6.86; and N 19.57%. ESI + MS: [C35H43N9O4Na1]+ Found: 676.33365.
6-{4-[(4-{[(5-Cyano-3,3-dimethyl-8-propyl-3,4-dihydro-1H-pyrano [3,4-c]pyridin-6-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-1-ethyl-3,3-dimethyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7t). Colorless solid; yield 81%; mp 170–172 °C; IR ν/cm–1: 1675 (C=O) and 2222 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.03 (t, J = 7.4 Hz, 3H, C2H4CH3), 1.24 (t, J = 7.4 Hz, 3H, CH2CH3), 1.27 (s, 6H, C(CH3)2), 1.28 (s, 6H, C(CH3)2), 1.74–1.87 (m, 2H, CH2CH2CH3), 2.53–2.62 (m, 4H, C2H5CH2, CH2CH3), 2.72 (s, 2H, 4-CH2), 2.76 (s, 2H, 4’-CH2), 3.61–3.76 (m, 8H, C4H8N2), 4.60 (s, 2H, 1-CH2), 4.64 (s, 2H, 1′-CH2), 5.48 (s, 2H, NCH2), 5.55 (s, 2H, OCH2), and 7.95 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 10.88, 13.52, 20.17, 25.59, 25.67, 25.75, 26.45, 35.07, 37.73, 37.86, 41.19, 43.98, 47.39, 47.92, 50.35, 58.82, 58.95, 59.52, 68.98, 92.96, 93.05, 113.29, 115.59, 118.78, 120.67, 125.41, 141.57, 147.86, 148.96, 158.63, 159.13, 159.38, 160.94, and 163.78. Anal. calcd. for C36H45N9O4: C 64.75; H 6.79; and N 18.88%. Found: C 65.13; H 6.99; and N 19.15%.
6-{4-[(4-{[(5-Cyano-3,3-dimethyl-8-propyl-3,4-dihydro-1H-pyrano [3,4-c]pyridin-6-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)acetyl]piperazin-1-yl}-3,3-dimethyl-8-propyl-3,4-dihydro-1H-pyrano [3,4-c]pyridine-5-carbonitrile (7u). Colorless solid; yield 88%; mp 211–213 °C; IR ν/cm–1: 1662 (C=O), and 2209, 2231 (C≡N). 1H NMR (300 MHz, DMSO-d6/CCl4, 1/3): δ 1.00 (t, J = 7.3 Hz, 3H, CH2CH3), 1.03 (t, J = 7.3 Hz, 3H, CH2CH3), 1.28 (s, 12H, 2C(CH3)2), 1.67–1.87 (m, 4H, 2CH2CH3), 2.53–2.62 (m, 4H, 2CH2C2H5), 2.72 (s, 2H, 4-CH2), 2.76 (s, 2H, 4′-CH2), 3.60–3.76 (m, 8H, C4H8N2), 4.60 (s, 2H, 1-CH2), 4.65 (s, 2H, 1′-CH2), 5.48 (s, 2H, NCH2), 5.55 (s, 2H, OCH2), and 7.96 (s, 1H, CHtriazole). 13C NMR (75 MHz, DMSO-d6/CCl4, 1/3): δ 13.53, 20.01, 20.17, 25.68, 25.71, 25.74, 35.07, 35.20, 37.73, 37.88, 41.19, 43.97, 47.41, 47.98, 50.35, 58.95, 59.51, 68.93, 68.97, 92.94, 93.17, 113.30, 115.58, 119.08, 120.67, 125.43, 141.57, 147.96, 148.96, 158.55, 158.64, 159.06, 160.94, and 163.78. Anal. calcd. for C37H47N9O4: C 65.18; H 6.95; and N 18.49%. Found: C 65.49; H 7.12; and N 18.72%. ESI + MS: [C37H47N9O4Na1]+ Found: 704.36494.

3.2. Biological Evaluation

Compounds were studied for their possible neurotropic activities (anticonvulsant, sedative, and anti-anxiety activities) as well as for side effects on 450 white mice of both sexes weighing 18–24 g and 50 male rats of the Wistar line weighing 120–140 g. All groups of animals were maintained at 25 ± 2 °C in the same room on a common food ration. As reference compounds, the known antiepileptic drug ethosuximide and tranquilizer diazepam were used. All the biological experiments were carried out in full compliance with the European Convention for the Protection of Vertebrates. All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Strasbourg (France; ETS No 123, Strasbourg, 03/18/1986).

3.2.1. Evaluation of the Anticonvulsant Activity of the Synthesized Compounds

The anticonvulsant effect of the newly synthesized compounds was investigated by tests comprising pentylenetetrazole, thiosemicarbazide convulsions, and maximal electroshock (MES). Outbred mice (weight 18–22 g) were used for the study. In the case of convulsions induced by PTZ, it was injected subcutaneously at 90 mg/kg, which induced convulsions in 95% of animals (CD 95%). Each animal is placed into an individual plastic cage for observation lasting 1 h. Seizures and clonic convulsions were recorded. Substances were administered intraperitoneally (i.p.) at doses of 10–200 mg/kg in suspension with carboxymethylcellulose and Tween-80 45 min before administration of PTZ and applying electrical stimulation. The control animals were administered as an emulsifier. Every dose of each test compound was studied in six animals.
The MES test is used as an animal model for the generalized tonic seizures of epilepsy. The parameters of MES were: 50 mA, duration of 0.2 s, and an oscillation frequency of 50 imp/s. The anticonvulsant properties of compounds were assessed by their prevention of the tonic-extensor phase of convulsions.
Thiosemicarbazide, an antimetabolite of GABA inhibitor (glutamic acid decarboxylase) in the brain, is administered subcutaneously to mice at a dose of 18 mg/kg as a 0.5% solution, which causes clonic convulsions in animals. Anti-thiosemicarbazide activity was evaluated based on the latency time of the onset of seizures. Compounds were administered intraperitoneally at doses of 100 mg/kg in suspension with carboxymethylcellulose and Tween-80 45 min before administration of thiosemicarbazide.
The comparative drug ethosuximide was administered in doses of 200 mg/kg and diazepam in doses of 2 mg/kg.

3.2.2. Evaluation of the Psychotropic Properties of the Synthesized Compounds

Psychotropic properties of selected compounds were studied by the following tests: “open field”, “elevated plus maze” (EPM), “forced swimming”, and “test for learning and memory”.
Open field test. The research-motor behavior of rats was studied on a modified “open field” model. For this purpose, an installation was used, the bottom of which is divided into squares with holes (cells). Experiments were performed in the daytime with natural light. Within 5 min of the experiment, the indicators of sedative and activating behavior were determined, namely the number of horizontal movements, standing on the hind legs (vertical movements), and sniffing of the cells. The number of animals on this model was eight for each compound, control, and reference drug. The studied compounds were administered to rats at the most effective dose of 50 mg/kg intraperitoneally as a suspension with methylcarboxycellulose and Tween-80.
Elevated plus maze—EPM test. Anti-anxiety and sedative effects were studied on mouse a model of the “elevated plus maze”. The labyrinth is a cruciform machine raised above the floor, with a pair of open and closed sleeves opposed to each other. Normal animals prefer to spend most of their time in the closed (dark) sleeves of the labyrinth. The anxiolytic effect of the compounds was estimated by the increase in the number of entries into open (light) sleeves and the time spent in them without increasing the total motor activity. This records the time spent in the closed sleeve and the number of attempts to enter the installation center. In the above model, the test compounds and the reference drug were injected intraperitoneally before the experiments. The control animals were administered as an emulsifier. Results were processed statistically (p < 0.05).
Forced swimming test. To assess “despair and depression”, the “compelling swimming” model was used. Experimental animals were forced to swim in a glass container (height 22 cm, diameter 14 cm), filled 1/3 with water. Intact mice swim very actively, but soon they will be forced to immobilize. The latent period of immobilization, the total duration of active swimming and immobilization are fixed at 6 min (the experiments were conducted under natural light).
Test for learning and memory. The antiamnesic properties of the compounds were studied using an electroshock amnesia model modified by J. Bures, O. Buresova [43]. In rats, a conditioned passive avoidance reaction (CRPA) to a dark-light setting was developed, while the training of the animals with CRPA was recorded. The residence times in the light and dark compartments were recorded for 5 min (300 s). Then, in the dark compartment, the animal received a single current shock (0.4 mA) through the electrode floor (training). To obtain amnesia, a maximum electroconvulsive seizure is induced in animals (conducting a maximum electric current of 50 Hz for 0.2 s through corneal electrodes). Conducting an electric shock immediately after training causes the erasure of the memory trace. The test for reproduction is carried out 24 h after training—after the development of CRPA. During this period, the control animals forget the training and prefer to be in the dark part of the chamber. An increase in the time spent by rats in the light compartment compared to the control on the second day indicates the presence of antiamnestic properties of the compounds.

3.2.3. Evaluation of Coordination of Movement in the Rotating Rod Test

Adverse neurotoxic (muscle relaxant) effects of compounds were studied at doses of 50 to 500 mg/kg when administered intraperitoneally, as well as reference drugs in effect at anticonvulsant doses. Myorelaxation was investigated with the test of a “rotating rod” in mice. To this end, mice were planted on a metal rod with a corrugated rubber coating, which rotated at a speed of 5 revolutions per minute. The number of animals that cnot stay on it for 2 min was determined. To determine the ED50, neurotoxic TD50, and LD50, the statistical method of penetration by Litchfield and Wilcoxon was used. The acute toxicity (LD50) was determined by calculating the number of dead animals after 24 h of exposure at doses of 100–1020 mg/kg.

3.3. Docking Studies

Docking studies were performed using AutoDock 4 (ver. 4.2.6) into the 3D structures of the GABAA receptor (PDB code: 4COF), SERT transporter (PDB code: 3F3A), and 5-HT1A receptor (PDB code: 3NYA), retrieved from the protein data bank (PDB). For the final preparation of both ligands and proteins, Wizard of AutoDock Tools 1.5.6 was used.
All molecules were sketched in the chemdraw12.0 program. The geometry of built compounds was optimized using the molecular mechanical force fields 94 (MMFF94) energy via the program LigandScout (ver. 4.4.5); partial charges were also calculated; conformers of each ligand were generated; and the one with the best conformation was maintained and saved as a mol2 file that was passed to ADT for pdbqt file preparation. There, polar hydrogen was added to each structure, followed by computing the Gasteiger and Kollman charges and the torsions. The region of interest, used by Autodock4 for docking runs and by Autogrid4 for affinity grid map preparation, was defined in such a way as to comprise the whole catalytic binding site using a grid size of 110 × 110 × 110 xyz points with a grid spacing of 0.375 Å. The grid center was calculated at x = –20.558, y = –19.574 and z = 127.994 for GABAA receptor, at x = –19.7478, y = 22.417, and z = –14.3006 for the SERT transporter and at x = –8.207, y = 9.305, and z = –48.61 for the 5-HT1A receptor. For the simulation, default values for quaternation, translation, and torsion steps were applied. The Lamarckian Genetic Algorithm with default parameters was applied for minimization. The number of docking runs was 100. After docking, the 100 solutions were clustered into groups with RMS lower than 1.0 Ε. The clusters were ranked by the lowest energy representative of each cluster. Upon completion of docking, the best poses were screened by examination of binding energy (ΔGbinding, kcal/mol) and cluster number. In order to describe the ligand-binding pocket interactions, the top-ranked binding mode found by AutoDock in complex with the binding pocket of an enzyme was selected. The Accelrys Discovery Studio 2020 Client (Dassault Systèmes presence, Wlatham, MA, USA) [54,55] and LigandScout (ver. 4.4.5) were used for the graphical representations of all ligand-protein complexes.

3.4. Drug Likeness

Absorption, distribution profile, and drug-likeness model score of compounds were predicted using the Molsoft software [56] Molsoft LLC., San Diego, CA, USA, and the ADMET structure-activity relationship server, admetSAR version 2.0, Shanghai, China [57] via ChemAxon’s Marvin JS structure drawing tool.

4. Conclusions

In summary, new original hybrids were synthesized based on the biologically active bicyclic pyridine derivatives via a Cu-catalyzed azide-alkyne 1,3-dipolar cycloaddition. The studies have shown that the alkylation of 3(6)-hydroxy derivatives of bicyclic pyridines leads to the formation of O-alkylated derivatives 2 in high yields, and only traces of N-alkylated derivatives are observed.
The anticonvulsant activity, combined with some psychotropic properties, of the new hybrids was evaluated. The biological assays evidenced that 15 of the studied compounds exhibited a high anticonvulsant activity due to their antagonism of pentylenetetrazole, which was superior to ethosuximide but inferior to diazepam. Compounds 7a, d, g, j, m, and o displayed the highest therapeutic indexes among the tested ones. The compounds at 100 mg/kg dose increased latency of thiosemicarbazide seizures to 1.5–4.37 times compared to the control and reference drug diazepam. The findings suggest some GABA-ergic activity involvement in the mechanism of action of the substances. The toxicity of compounds is low and does not induce muscle relaxation at the studied doses. According to the study of psychotropic activity, it was found that the selected compounds had activating behavior, and anxiolytic effects on the models of “open field” (the data obtained indicated the anxiolytic (anti-anxiety) activity of the compounds, especially pronounced in the compounds 7a, d, g, m, j, and o) and EPM (after the administration of all compounds, the experimental animals, in contrast to the control animals, enter the open arms and stay there from 6.6 (compound 7g) to 66.4 (compound 7m) sec. On the “forced swimming” model, some of the selected compounds (7a, c, g, h, j, m, o, and q) increased the active swimming time and the latent period of first immobilization, exhibiting some antidepressant effect similarly to diazepam. On the model of electroshock retrograde amnesia—conditioned response of passive avoidance (CRPA), the administration of compounds at a dose of 50 mg/kg per day, except for compound 7j, caused some increase in the time of reproduction of the reflex in animals. Statistically, these values are significantly different from the control values and indicate the antiamnesic effect of the compounds.
Molecular docking studies were in agreement with experimental data.
The prediction of drug likeness revealed that the drug-likeness score was found to be from 0.33 to 0.83, indicating the possibility for these compounds to be treated as drug candidates. Furthermore, according to prediction, all the tested molecules were able to pass the blood-brain barrier (BBB). The admetSAR server revealed that all compounds are both good P-glycoprotein substrates (65–73%) and inhibitors (74–78%).
Thus, compounds 7a, d, g, j, and m, in particular, show high anticonvulsant activity by the corazol antagonism test and simultaneously express psychotropic properties. These five most active substances contain a pyrano [3,4-c]pyridine cycle with a methyl group in the pyridine ring of their structure.
The obtained results demonstrated that the compounds can be effective in various types of human epilepsy associated with mental disorders.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28030921/s1. The copies of 1H-NMR, 13C-NMR, and MS spectra for newly synthesized compounds have been submitted along with the manuscript.

Author Contributions

S.N.S., E.K.H., H.A.Y. and A.A.H. performed experiments on the synthesis of all compounds and analyzed the results. R.G.P. and T.A.A. performed the neurotropic activity experiments. A.G. and A.P. performed docking studies. A.G.A. performed and analyzed the crystallographic data. L.Z. and R.Z. recorded and analyzed the MS spectra. D.S. and V.G.K. reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

The work was supported by the Science Committee of RA, through the frames of the research project No 21AG-1D036.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethics committee of the Yerevan State Medical University (YSMU, Yerevan, Armenia) (protocol code 5 and date of approval: 24 March 2016), it followed the “Principles of laboratory animal care” and carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC).

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of all compounds 1–7 are available from the authors.

References

  1. World Health Organization. Fact Sheets: Epilepsy. Available online: https://www.who.int/news-room/fact-sheets/detail/epilepsy (accessed on 9 February 2022).
  2. Forsgren, L.; Beghi, E.; Oun, A.; Sillanpä, M. The epidemiology of epilepsy in Europe—A systematic review. Eur. J. Neurol. 2005, 12, 245–253. [Google Scholar] [CrossRef]
  3. Park, K.M.; Kim, S.E.; Lee, B.I. Antiepileptic drug therapy in patients with drug-resistant epilepsy. J. Epilepsy Res. 2019, 9, 14–26. [Google Scholar] [CrossRef] [PubMed]
  4. Voronkova, K.V.; Golosnaya, G.S.; Lemeshko, I.D.; Petrukhin, A.S. Advantages of broad spectrum antiepileptic drugs in treatment of epilepsy. Epilepsy Paroxysmal Cond. 2017, 9, 79–85. (In Russian) [Google Scholar] [CrossRef]
  5. Robert, M.A. Hirschfeld: Guideline Watch: Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd ed.; American Psychiatric Association: Arlington, VA, USA, 2002; pp. 1–9. [Google Scholar]
  6. Meunier, B. Hybrid molecules with a dual mode of action: Dream or reality? Acc. Chem. Res. 2008, 41, 69–77. [Google Scholar] [CrossRef] [PubMed]
  7. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A.J. Recent developments in fragment-based drug discovery. J. Med. Chem. 2008, 51, 3661–3680. [Google Scholar] [CrossRef]
  8. Tietze, L.F.; Bell, H.P.; Chandrasekhar, S. Natural product hybrids as new leads for drug discovery. Angew. Chem. Int. Ed. 2003, 42, 3996–4028. [Google Scholar] [CrossRef]
  9. Mehta, G.; Singh, V. Hybrid systems through natural product leads: An approach towards new molecular entities. Chem. Soc. Rev. 2002, 31, 324–334. [Google Scholar] [CrossRef] [PubMed]
  10. Tsogoeva, S.B. Recent progress in the development of synthetic hybrids of natural or unnatural bioactive compounds for medicinal chemistry. Mini-Rev. Med. Chem. 2010, 10, 773–793. [Google Scholar] [CrossRef] [PubMed]
  11. Arndt, S.; Emde, U.; Bäuerle, S.; Friedrich, T.; Grubert, L.; Koert, U. Quinone–annonaceous acetogenins: Synthesis and complex I inhibition studies of a new class of natural product hybrids. Chem. Eur. J. 2001, 7, 993–1005. [Google Scholar] [CrossRef] [PubMed]
  12. Horwedel, C.; Tsogoeva, S.B.; Wei, S.; Efferth, T. Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. J. Med. Chem. 2010, 53, 4842–4848. [Google Scholar] [CrossRef]
  13. Reiter, C.; Herrmann, A.; Çapci, A.; Efferth, T.; Tsogoeva, S.B. New artesunic acid homodimers: Potent reversal agents of multidrug resistance in leukemia cells. Bioorg. Med. Chem. 2012, 20, 5637–5641. [Google Scholar] [CrossRef] [PubMed]
  14. Sirakanyan, S.N.; Hrubša, M.; Spinelli, D.; Dias, P.; Kartsev, V.; Carazo, A.; Hovakimyan, A.A.; Pourová, J.; Hakobyan, E.K.; Karlíčková, J.; et al. Synthesis of 3,3-dimethyl-6-oxopyrano [3,4-c]pyridines and their antiplatelet and vasodilatory activity. J. Pharm. Pharmacol. 2022, 74, 887–895. [Google Scholar] [CrossRef] [PubMed]
  15. Sirakanyan, S.N.; Akopyan, E.K.; Paronikyan, R.G.; Nazaryan, I.M.; Akopyan, A.G.; Ovakimyan, A.A. Synthesis and neurotropic activity of piperazino-derivatives of pyrano [3,4-c]pyridines. Pharm. Chem. J. 2019, 53, 495–499. [Google Scholar] [CrossRef]
  16. Sirakanyan, S.N.; Noravyan, A.S.; Dzhagatspanyan, I.A.; Nazaryan, I.M.; Ovakimyan, A.A.; Akopyan, A.G.; Avetisyan, N.G. Synthesis and neurotropic activity of new derivatives of piperazino-substituted pyrano [3,4-c]pyridines. Pharm. Chem. J. 2013, 46, 591–594. [Google Scholar] [CrossRef]
  17. Sirakanyan, S.N.; Kartsev, V.G.; Spinelli, D.; Geronikaki, A.; Petrou, A.; Ivanov, M.; Glamoclija, J.; Sokovic, M.; Hakobyan, E.; Hovakimyan, A.A. Synthesis and antimicrobial activity of new 2-piperazin-1-yl-N-1,3-thiazol-2-ylacetamides of cyclopenta[c]pyridines and pyrano[3,4-c]pyridines. Arch. Pharm. 2021, 354, 2000208. [Google Scholar] [CrossRef] [PubMed]
  18. Gonnet, L.; Baron, M.; Baltas, M. Synthesis of biologically relevant 1,2,3- and 1,3,4-triazoles: From classical pathway to green chemistry. Molecules 2021, 26, 5667. [Google Scholar] [CrossRef]
  19. Pereira, D.; Pinto, M.; Correia-da-Silva, M.; Cidade, H. Recent advances in bioactive flavonoid hybrids linked by 1,2,3-triazole ring obtained by click chemistry. Molecules 2022, 27, 230. [Google Scholar] [CrossRef] [PubMed]
  20. Agalave, S.G.; Maujan, S.R.; Pore, V.S. Click chemistry: 1,2,3-triazoles as pharmacophores. Chem. Asian J. 2011, 6, 2696–2718. [Google Scholar] [CrossRef]
  21. Ramachary, D.B.; Shashank, A.B.; Karthik, S. An organocatalytic azide–aldehyde [3+2] cycloaddition: High-yielding regioselective synthesis of 1,4-disubstituted 1,2,3-triazoles. Angew. Chem. Int. Ed. 2014, 53, 10420–10424. [Google Scholar] [CrossRef]
  22. Quan, Z.-J.; Xu, Q.; Zhang, Z.; Da, Y.-X.; Wang, X.-C. Copper-catalyzed click synthesis of functionalized 1,2,3-triazoles with 3,4-dihydropyrimidinone or amide group via a one-pot four-component reaction. Tetrahedron 2013, 69, 881–887. [Google Scholar] [CrossRef]
  23. Seus, N.; Saraiva, M.T.; Alberto, E.E.; Savegnago, L.; Alves, D. Selenium compounds in Click Chemistry: Copper catalyzed 1,3-dipolar cycloaddition of azidomethyl arylselenides and alkynes. Tetrahedron 2012, 68, 10419–10425. [Google Scholar] [CrossRef]
  24. Sirakanyan, S.N.; Ghochikyan, T.V.; Spinelli, D.; Galstyan, A.S.; Geronikaki, A.; Samvelyan, M.A.; Hakobyan, E.K.; Hovakimyan, A.A. Synthesis of novel 1,2,3-triazole-based hybrids via click reaction. Arkivoc 2022, part ii, 7–21. [Google Scholar] [CrossRef]
  25. Sirakanyan, S.N.; Geronikaki, A.; Kartsev, V.; Hakobyan, E.K.; Hovakimyan, A.A. One-pot synthesis of 3-oxocycloalka[c]pyridines. Russ. J. Org. Chem. 2021, 57, 1748–1752. [Google Scholar] [CrossRef]
  26. Sirakanyan, S.N.; Spinelli, D.; Kartsev, V.; Geronikaki, A.; Hakobyan, E.K.; Ayvazyan, A.G.; Tamazyan, R.A.; Hovakimyan, A.A. A study of the regiochemistry in the synthesis of pyrano[3,4-c]pyridines. Curr. Org. Chem. 2021, 25, 1704–1714. [Google Scholar] [CrossRef]
  27. Sirakanyan, S.N.; Spinelli, D.; Geronikaki, A.; Zuppiroli, L.; Zuppiroli, R.; Kartsev, V.; Hakobyan, E.K.; Yegoryan, H.A.; Hovakimyan, A.A. Synthesis of 1-amino-3-oxo-2,7-naphthyridines via Smiles rearrangement: A new approach in the field of chemistry of heterocyclic compounds. Inter. J. Mol. Sci. 2022, 23, 5904. [Google Scholar] [CrossRef]
  28. Sirakanyan, S.N.; Spinelli, D.; Geronikaki, A.; Kartsev, V.; Hakobyan, E.K.; Petrou, A.; Paronikyan, R.G.; Nazaryan, I.M.; Akopyan, H.H.; Hovakimyan, A.A. Synthesis and neurotropic activity of new heterocyclic systems: Pyridofuro[3,2-d]pyrrolo[1,2-a]pyrimidines, pyridofuro[3,2-d]pyrido[1,2-a]pyrimidines and pyridofuro[3′,2′:4,5]pyrimido[1,2-a]azepines. Molecules 2021, 26, 3320. [Google Scholar] [CrossRef]
  29. Vogel, H.G.; Vogel, W.H. Psychotropic and neurotropic activity. In Drug Discovery and Evaluation: Pharmacological Assays; Vogel, H.E., Ed.; Springer: Berlin/Heidelberg, Germany, 2008; pp. 569–874. [Google Scholar]
  30. Loscher, W.; Schmidt, D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1988, 2, 145–181. [Google Scholar] [CrossRef] [PubMed]
  31. Swinyard, E.A. Experimental Models of Epilepsy; Purpura, D.P., Penry, J.K., Tower, D., Woodbury, D.M., Walter, R., Eds.; Raven Press: New York, NY, USA, 1992; pp. 433–458. [Google Scholar]
  32. Katzung, B. Drugs Used in Generalized Seizures, Basic and Clinical pharmacology, Large Medical Books, 9th ed.; McGraw-Hill: New York, NY, USA, 2003. [Google Scholar]
  33. Yuen, E.; Troconiz, I. Can pentylenetetrazole and maximal electroshock rodent seizure models quantitatively predict antiepileptic efficacy in humans? Seizure 2015, 24, 21–27. [Google Scholar] [CrossRef] [Green Version]
  34. Luszczki, J.J.; Kominek, M.; Florek-Luszczki, M.; Tchaytchian, D.A.; Kocharov, S.L.; Zolkowska, D. Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Epilepsy Res. 2012, 100, 27–36. [Google Scholar] [CrossRef]
  35. Löscher, W.; Fassbender, C.; Nolting, B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991, 8, 79–94. [Google Scholar] [CrossRef]
  36. Litchfield, J.T.; Wilcoxon, F.J. A simplified method of evaluating dose-effect experiments. Pharmacol. Exp. Ther. 1949, 96, 99–113. Available online: https://jpet.aspetjournals.org/content/96/2/99 (accessed on 22 December 2022).
  37. Mashkovsky, M.D. Medicines, 16th ed.; New Wave: Moscow, Russia, 2021; p. 1216. [Google Scholar]
  38. File, S.E. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav. Brain Res. 2001, 125, 151–157. [Google Scholar] [CrossRef] [PubMed]
  39. Prut, L.; Belzung, C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review. Eur. J. Pharmacol. 2003, 463, 3–33. [Google Scholar] [CrossRef] [PubMed]
  40. Pellow, S.; Chopin, P.; File, S.E.; Briley, M. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14, 149–167. [Google Scholar] [CrossRef] [PubMed]
  41. Graeff, F.G.; Netto, C.F.; Zangrossi, H., Jr. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 1998, 23, 237–246. [Google Scholar] [CrossRef] [PubMed]
  42. Porsolt, R.D.; Anton, G.; Blavet, N.; Jalfre, M. Behavioural despair in rats: A new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 1978, 47, 379–391. [Google Scholar] [CrossRef]
  43. Buresh, Y.; Bureshova, O.; Houston, D.P. Methods and Basic Experiments for Investigation of the Brain and Behavior; Vysshaya Shkola: Moscow, Russia, 1991; pp. 175–189. (In Russian) [Google Scholar]
  44. Rogawski, M.A.; Löscher, W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 2004, 5, 553–564. [Google Scholar] [CrossRef] [Green Version]
  45. Kammerer, M.; Rassner, M.P.; Freiman, T.M.; Feuerstein, T.J. Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2011, 384, 47–57. [Google Scholar] [CrossRef]
  46. Miller, P.S.; Aricescu, A.R. Crystal structure of a human GABAA receptor. Nature 2014, 512, 270–275. [Google Scholar] [CrossRef] [Green Version]
  47. Saier, M.H., Jr. A functional-phylogenetic classification system for transmembrane solute transporters. Microbiol. Mol. Biol. Rev. 2000, 64, 354–411. [Google Scholar] [CrossRef] [Green Version]
  48. Perrone, R.; Berardi, F.; Colabufo, N.A.; Lacivita, E.; Larizza, C. Design and synthesis of long-chain arylpiperazines with mixed affinity for serotonin transporter (SERT) and 5-HT1A receptor. J. Pharm. Pharmacol. 2005, 57, 1319–1327. [Google Scholar] [CrossRef] [PubMed]
  49. Blier, P. Pharmacology of rapid-onset antidepressant treatment strategies. J. Clin. Psychiatry 2001, 62 (Suppl. S15), 12–17. [Google Scholar] [PubMed]
  50. Singh, S.K.; Piscitelli, C.L.; Yamashita, A.; Gouaux, E. A competitive inhibitor traps LeuT in an open-to-out conformation. Science 2008, 322, 1655–1661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Kuipers, W.; Link, R.; Standaar, P.J.; Stoit, A.R.; Van Wijngaarden, I.; Leurs, R.; Ijzerman, A.P. Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor. Mol. Pharmacol. 1997, 51, 889–896. [Google Scholar] [CrossRef] [Green Version]
  52. Wacker, D.; Fenalti, G.; Brown, M.A.; Katritch, V.; Abagyan, R.; Cherezov, V.; Stevens, R.C. Conserved Binding Mode of Human β2 Adrenergic Receptor Inverse Agonists and Antagonist Revealed by X-ray Crystallography. J. Am. Chem. Soc. 2010, 132, 11443–11445. [Google Scholar] [CrossRef] [Green Version]
  53. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Cryst. 2015, C71, 3–8. [Google Scholar] [CrossRef] [Green Version]
  54. Bandaru, S.; Tiwari, G.; Akka, J.; Marri, V.K.; Alvala, M.; Gutlapalli, V.R.; Nayarisseri, A.; Mundluru, H.P. Identification of high affinity bioactive Salbutamol conformer directed against mutated (Thr164Ile) beta 2 adrenergic receptor. Curr. Top. Med. Chem. 2015, 15, 50–56. [Google Scholar] [CrossRef]
  55. Accelrys Discovery Studio® Visualizer 3.5.0.12158, (Copyright© 2005-12, Accelrys Software Inc.) was used for molecular visualizations; Accelrys Software Inc.: San Diego, CA, USA, 2005.
  56. Molsoft Software. Available online: https://molsoft.com/mprop/ (accessed on 22 December 2022).
  57. Yang, H. admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics 2018, 35, 1067–1069. [Google Scholar] [CrossRef]
Molecules 28 00921 sch001 550
Scheme 1. Alkylation of 3(6)-hydroxypyridines 1.
Scheme 1. Alkylation of 3(6)-hydroxypyridines 1.
Molecules 28 00921 sch001
Molecules 28 00921 g001 550
Figure 1. The molecular structures of compounds 2f (left) and 3f (right), respectively, with thermal displacement ellipsoids drawn at the 50% probability level.
Figure 1. The molecular structures of compounds 2f (left) and 3f (right), respectively, with thermal displacement ellipsoids drawn at the 50% probability level.
Molecules 28 00921 g001
Molecules 28 00921 sch002 550
Scheme 2. Synthesis of 3(6)-[4-(azidoacetyl)piperazin-1-yl][c]pyridines 6. 4–6 a: R = Me; b: R = Et; c: R = Pr.
Scheme 2. Synthesis of 3(6)-[4-(azidoacetyl)piperazin-1-yl][c]pyridines 6. 4–6 a: R = Me; b: R = Et; c: R = Pr.
Molecules 28 00921 sch002
Molecules 28 00921 sch003 550
Scheme 3. Synthesis of targeted hybrids 7a–u.
Scheme 3. Synthesis of targeted hybrids 7a–u.
Molecules 28 00921 sch003
Molecules 28 00921 g002 550
Figure 2. Graphical representation of anticonvulsant activity and TI of the hybrids 7a, c, d, f–j, m–o, q, r, t, u. * indicates p = 0.05 at the probability level.
Figure 2. Graphical representation of anticonvulsant activity and TI of the hybrids 7a, c, d, f–j, m–o, q, r, t, u. * indicates p = 0.05 at the probability level.
Molecules 28 00921 g002
Molecules 28 00921 g003 550
Figure 3. Graphical representation of activity of compounds 7a, c, d, f–j, m–o, q, r, t, u, ethosuximide, and diazepam in the “open field” model.
Figure 3. Graphical representation of activity of compounds 7a, c, d, f–j, m–o, q, r, t, u, ethosuximide, and diazepam in the “open field” model.
Molecules 28 00921 g003
Molecules 28 00921 g004 550
Figure 4. Graphical representation of the influence of compounds 7a, c, d, f–j, m–o, q, r, t, u, and compared drugs on the EPM model (5 min of research). * indicates p = 0.05 at the probability level.
Figure 4. Graphical representation of the influence of compounds 7a, c, d, f–j, m–o, q, r, t, u, and compared drugs on the EPM model (5 min of research). * indicates p = 0.05 at the probability level.
Molecules 28 00921 g004
Molecules 28 00921 g005 550
Figure 5. Graphical representation of the effect of compounds 7a, c, d, f–j, m–o, q, r, t, and u, and reference preparations on “forced swimming” (study for 6 min). * indicates p = 0.05 at the probability level.
Figure 5. Graphical representation of the effect of compounds 7a, c, d, f–j, m–o, q, r, t, and u, and reference preparations on “forced swimming” (study for 6 min). * indicates p = 0.05 at the probability level.
Molecules 28 00921 g005
Molecules 28 00921 g006 550
Figure 6. Graphical representation of the characterization of the parameters of amnestic functions on the model of electroshock retrograde amnesia after administration of hybrid compounds 7a, d, g, i, j, m, and n (study for 5 min).
Figure 6. Graphical representation of the characterization of the parameters of amnestic functions on the model of electroshock retrograde amnesia after administration of hybrid compounds 7a, d, g, i, j, m, and n (study for 5 min).
Molecules 28 00921 g006
Molecules 28 00921 g007 550
Figure 7. Docked confirmation alignment of the re-docked initial inhibitor Benzamidine (blue) and the co-crystalized ligand to the structure 4COF (RMSD: 0.34 Å).
Figure 7. Docked confirmation alignment of the re-docked initial inhibitor Benzamidine (blue) and the co-crystalized ligand to the structure 4COF (RMSD: 0.34 Å).
Molecules 28 00921 g007
Molecules 28 00921 g008 550
Figure 8. Docked conformation of the diazepam and GABAA receptor complex.
Figure 8. Docked conformation of the diazepam and GABAA receptor complex.
Molecules 28 00921 g008
Molecules 28 00921 g009 550
Figure 9. Docked pose of compound 7j and the GABAA receptor complex; (A) 2D diagram, (B) 3D representation. red lines show the hydrogen bonds and yellow spheres represent hydrophobic interactions.
Figure 9. Docked pose of compound 7j and the GABAA receptor complex; (A) 2D diagram, (B) 3D representation. red lines show the hydrogen bonds and yellow spheres represent hydrophobic interactions.
Molecules 28 00921 g009
Molecules 28 00921 g010 550
Figure 10. Docked confirmation alignment of the re-docked initial inhibitor L-Tryptophan (blue) and the co-crystalized to the structure 3F3A (magenta, RMSD: 0.86 Å).
Figure 10. Docked confirmation alignment of the re-docked initial inhibitor L-Tryptophan (blue) and the co-crystalized to the structure 3F3A (magenta, RMSD: 0.86 Å).
Molecules 28 00921 g010
Molecules 28 00921 g011 550
Figure 11. (A) Docked pose of compound 7a and the SERT transporter complex; (B) 2D ligand interaction diagram for the docked ligand.
Figure 11. (A) Docked pose of compound 7a and the SERT transporter complex; (B) 2D ligand interaction diagram for the docked ligand.
Molecules 28 00921 g011
Molecules 28 00921 g012 550
Figure 12. Docked conformation alignment of the re-docked initial inhibitor alprenolol (blue) and the co-crystalized ligand (green) to the structure 3NYA (RMSD: 0.98 Å).
Figure 12. Docked conformation alignment of the re-docked initial inhibitor alprenolol (blue) and the co-crystalized ligand (green) to the structure 3NYA (RMSD: 0.98 Å).
Molecules 28 00921 g012
Molecules 28 00921 g013 550
Figure 13. (A) 2D ligand interaction diagram for docked compound 7a. (B) Docked pose of compound 7a (blue) and alprenolol (magenta) within the 5-HT1A receptor.
Figure 13. (A) 2D ligand interaction diagram for docked compound 7a. (B) Docked pose of compound 7a (blue) and alprenolol (magenta) within the 5-HT1A receptor.
Molecules 28 00921 g013
Molecules 28 00921 g014 550
Figure 14. Drug-likeness model score of compound 7a. Green coloring indicates non drug-like behavior, and the blue coloring indicates drug-like behavior.
Figure 14. Drug-likeness model score of compound 7a. Green coloring indicates non drug-like behavior, and the blue coloring indicates drug-like behavior.
Molecules 28 00921 g014
Table
Table 1. 1(8)-Alkyl-3(6)-(prop-2-yn-1-yloxy)pyridines 2a–i and 3f.
Table 1. 1(8)-Alkyl-3(6)-(prop-2-yn-1-yloxy)pyridines 2a–i and 3f.
CompoundXnR1R2Yield (%)
2aCH20Hi-Pr73
2bCH21HMe71
2cCH21Hi-Pr78
2dCH21H2-furyl74
2eO1MeMe75
2fO1MeEt70
2gO1Men-Pr76
2hN-Pri1H(CH2)3N(CH2)372
2iN-Bn1H(CH2)3N(CH2)373
3fO1MeEt10
Table
Table 2. Crystallographic and experimental data for compounds 2f and 3f.
Table 2. Crystallographic and experimental data for compounds 2f and 3f.
Crystal Data
Compound2f3f
FormulaC16H18N2O2C16H18N2O2
Formula Weight270.32270.32
Crystal SystemTriclinicMonoclinic
Space groupP-1P21/c
a, b, c (Å)8.8582(18), 9.0602(18), 10.082(2)8.0680(16), 13.635(3), 12.783(3)
α, β, γ (deg)95.69(3), 113.99(3), 90.94(3)90, 90.72(3), 90
V (Å3)734.2(3)1406.1(5)
Z24
D(calc) (g/cm3)1.2231.277
μ(MoKa) (mm−1)0.0820.085
F(000)288576
Crystal Size (mm)0.44 × 0.38 × 0.320.36 × 0.30 × 0.26
Data Collection
Temperature (K)295293
Radiation (Å)MoKα 0.71073MoKα 0.71073
θmin, θmax (Deg)2.2, 30.02.2, 30.0
Dataset0 ≤ h ≤ 12; −12 ≤ k ≤ 12; −14 ≤ l ≤ 120 ≤ h ≤ 11; 0 ≤ k ≤ 19; −17 ≤ l ≤ 17
Tot., Uniq. Data, R (int)4526, 4271, 0.0104355, 4094, 0.021
Observed data (I > 2.0 σ(I))31752555
Refinement
Nref, Npar4271, 2534094, 253
R, wR2, S0.0470, 0.1454, 1.020.0523, 0.1502, 1.03
Table
Table 3. Targeted hybrids 7a–u.
Table 3. Targeted hybrids 7a–u.
NoHybridsNoHybrids
7aMolecules 28 00921 i0017lMolecules 28 00921 i002
7bMolecules 28 00921 i0037mMolecules 28 00921 i004
7cMolecules 28 00921 i0057nMolecules 28 00921 i006
7dMolecules 28 00921 i0077oMolecules 28 00921 i008
7eMolecules 28 00921 i0097pMolecules 28 00921 i010
7fMolecules 28 00921 i0117qMolecules 28 00921 i012
7gMolecules 28 00921 i0137rMolecules 28 00921 i014
7hMolecules 28 00921 i0157sMolecules 28 00921 i016
7iMolecules 28 00921 i0177tMolecules 28 00921 i018
7jMolecules 28 00921 i0197uMolecules 28 00921 i020
7kMolecules 28 00921 i021
Table
Table 4. Anticonvulsant activity and toxicity of the hybrids 7a, c, d, f–j, m–o, q, r, t, and u.
Table 4. Anticonvulsant activity and toxicity of the hybrids 7a, c, d, f–j, m–o, q, r, t, and u.
CompoundED50 *
mg/kg (by PTZ
antagonism)		TD50 *
mg/kg		LD50 *
mg/kg		TILatency of Convulsions, Induced by TSC, min
M ± MI **
Control−−– 10.0 ± 2.591.0
7a20 (16.5 ÷ 24)>500890 (742 ÷ 1068)44.543.0 ± 5.24.3
7c35 (23.0 ÷ 52.5)>500650 (542 ÷ 780)18.625.0 ± 4.12.5
7d16 (13.1 ÷ 19.5)>500800 (672 ÷ 952)44.441.2 ± 1.614.12
7f28 (22.2 ÷ 35.3)>500810 (686 ÷ 956)28.940.6 ± 1.114.06
7g18 (10.6 ÷ 30.6)>500680 (571 ÷ 809)37.828.4 ± 0.672.84
7h27 (18.4 ÷ 39.7)>500720 (590 ÷ 878)26.715.2 ± 1.21.5
7i34 (13.1 ÷ 19.5)>500695 (579 ÷ 834)20.441.0 ± 1.754.1
7j22 (18.6 ÷ 26)>500930 (775 ÷ 1116)42.341.0 ± 3.954.1
7m15 (12.5 ÷ 18)>500820 (572 ÷ 1000)54.736.6 ± 1.113.66
7n26 (18.6 ÷ 36.4)>500820 (689 ÷ 976)31.541.2 ± 1.614.12
7o28 (22.8 ÷ 34.4)>500800 (696 ÷ 920)28.630.4 ± 1.13.04
7q42 (33.6 ÷ 52.5)>500790 (648 ÷ 964)18.822.0 ± 2.22.2
7r26 (20.8 ÷ 32.5)>500710 (597 ÷ 845)27.339.4 ± 1.113.94
7t30 (24.2 ÷ 42)>500768 (640 ÷ 922)25.643.8 ± 4.344.38
7u32 (26.2 ÷ 39)>500680 (562 ÷ 823)21.343.8 ± 1.034.38
Ethosuximide155
(117.5 ÷ 204.5)		520
(413 ÷ 655)		1325
(1200 ÷ 1462)		8.517.0 ± 1.41.7
Diazepam0.5 (0.4 ÷ 0.7)2.7
(1.4 ÷ 5.5)		180
(128.5 ÷ 252)		3609.0 ± 2.50.9
* indicates p = 0.05 at the probability level; **—index of latent period of TSC seizures.
Table
Table 5. Activity of compounds 7a, c, d, f–j, m–o, q, r, t, u, ethosuximide, and diazepam in the “open field” model.
Table 5. Activity of compounds 7a, c, d, f–j, m–o, q, r, t, u, ethosuximide, and diazepam in the “open field” model.
Compound,
Dose 50 mg/kg		Amount (Absolute Data during 5 min) *
Horizontal DisplacementVertical
Displacement		Cells
Examination
Control21.6 ± 2.257.0 ± 2.142.4 ± 0.67
7a44.4 ± 10.1 **6.8 ± 3.428.6 ± 1.89 **
7c57.2 ± 12.85 **6.2 ± 1.034.2 ± 0.56 **
7d38.6 ± 5.18 **14.4 ± 3.98 **6.2 ±0.38**
7f39.2 ± 4.92 **10.8 ± 3.673.2 ± 1.03
7g49.0 ± 7.16 **9.0 ± 2.3410.0 ± 3.56 **
7h63.8 ± 14.02 **6.0 ± 0.896.8 ± 3.12 **
7i50.2 ± 5.5 **15.0 ± 4.28 **3.4 ± 1.89
7j54.6 ± 10.03 **10 ± 3.399.8 ± 3.53 **
7m59.8 ± 9.58 **12 ± 3.95 **13.4 ± 5.56 **
7n52.2 ± 12.2 **11.6 ± 2.5 **3.0 ± 0.89
7o73.0 ± 13.37 **9.6 ± 3.898.6 ± 3.25 **
7q60.2 ± 4.61 **8.8 ± 1.617.4 ± 2.42 **
7r30.0 ± 2.48 **2.2 ± 1.364.4 ± 1.89 **
7t46.0 ± 7.37 **10.6 ± 3.842.6 ± 0.79
7u41.8 ± 6.12 **3.6 ± 0.672.2 ± 1.03
Ethosuximide
(200 mg/kg)		26.8 ± 5.515.6 ± 1.80.6 ± 0.5
Diazepam
(2 mg/kg)		33.6 ± 6.1 **6.4 ± 1.4 **5.0 ±1.2 **
* indicates p ≤ 0.05 at the probability level; ** denotes differences that are statistically significant compared with the control.
Table
Table 6. Influence of compounds 7a, c, d, f–j, m-o, q, r, t, u, and compared drugs on the EPM model (5 min of research).
Table 6. Influence of compounds 7a, c, d, f–j, m-o, q, r, t, u, and compared drugs on the EPM model (5 min of research).
Compound,
50 mg/kg		Time Spent in Closed Arms
/s/ *		Number of Entries into the Closed Arms *Time Spent in
the Center
/s/ *		Time Spent in the Open Arms
/s/ *
Control269.2 ± 10.49.4 ± 1.628.2 ± 3.122.6 ± 1.6
7a262.6 ± 14.65.6 ± 2.1 **22.4 ± 3.9915.0 ± 2.1 **
7c244.0 ± 10.672.6 ± 1.4 **45.4 ± 4.7 **10.6 ± 2.1 **
7d264 ± 8.121.36 ± 0.8 **15.0 ± 3.6221.0 ± 3.2 **
7f264.0 ± 13.483.0 ± 0.89 **22.0 ± 6.3216.0 ± 2.09 **
7g237.8 ± 12.56.0 ± 1.67 **53.4 ± 3.53 **6.6 ± 2.3 **
7h246.6 ± 21.94.8 ± 1.34 **28.4 ± 2.3830.0 ± 2.4 **
7i242.0 ± 16.462.2 ± 0.61 **16.0 ± 5.242.0 ± 8.43 **
7j261.2 ± 20.85.9 ± 2.1 **19.2 ± 4.1519.6 ± 3.5 **
7m175.4 ± 6.236.4 ± 1.11 **48.8 ± 5.14 **66.4 ± 7.78 **
7n204.0 ± 14.21.4 ± 1.2 **82.0 ± 15.2 **12.0 ± 1.4 **
7o229.0 ± 11.25.8 ± 1.03 **61.0 ± 3.68 **10.0 ± 2.78 **
7q225.2 ± 13.875.0 ± 2.19 **50.8 ± 3.4 **24.0 ± 2.5 **
7r210.4 ± 10.33.4 ± 1.59 **83.0 ± 5.1 **7.0 ± 2.59 **
7t268.0 ± 5.561.6 ± 0.67 **9.0 ± 2.223.0 ± 5.51 **
7u243.8 ± 20.74.4 ± 2.1 **36.2 ± 2.38 **20.0 ± 3.12 **
Ethosuximide (200 mg/kg)247.2 ± 27.68.1 ± 2.552.8 ± 4.7 **–
Diazepam (2 mg/kg)257.5 ± 25.25.5 ± 1.1 **42.5 ± 3.9 **57.0 ± 4.2 **
* indicates p ≤ 0.05 at the probability level; ** denotes differences that are statistically significant compared with the control.
Table
Table 7. Effect of compounds 7a, c, d, f–j, m–o, q, r, t, and u, and reference preparations on “forced swimming” (study for 6 min).
Table 7. Effect of compounds 7a, c, d, f–j, m–o, q, r, t, and u, and reference preparations on “forced swimming” (study for 6 min).
Compound,
Dose 50 mg/kg		Latent Period First Immobilization (s)Total Time of Active Swimming (s) *Total Time of Immobilization (s) *
Control52.0 ± 5.4318.0 ± 8.3642.0 ± 7.24
7a79.0 ± 7.8 **341.4 ± 6.2 **18.6 ± 3.2 **
7c67.0 ± 5.3 **350.0 ± 11.62 **10.0 ± 4.1 **
7d48.0 ± 6.2300.0 ± 29.277.4 ± 7.1
7f52.0 ± 6.3296.0 ± 16.8566.0 ± 4.48
7g72.0 ± 6.3 **357.0 ± 13.5 **3.0 ± 0.6 **
7h73.0 ± 5.8 **358.0 ± 8.2 **2.0 ± 0.8 **
7i58.0 ± 7.1300.0 ± 19.3562.0 ± 5.04
7j66.9 ± 5.3 **346.0 ± 11.35 **14.0 ± 3.37 **
7m68.0 ± 7.2 **355.0 ± 5.0 **5.0 ± 1.2 **
7n53.0 ± 7.4324.0 ± 22.442.0 ± 12.04
7o72.0 ± 6.1 **358.0 ± 12.0 **2.0 ± 0.4 **
7q68.5 ± 7.2 **336.0± 25.3 **24.0 ± 2.9 **
7r50.0 ± 7.3324.0 ± 18.5536.0 ± 5.55
7t55.0 ± 5.2298.0 ± 16.6462.0 ± 6.77
7u46.0 ± 4.1276.0 ± 26.084.0 ± 12.5
Ethosuximide
(200 mg/kg)		55.0 ± 10.1262 ± 25.098.0 ± 9.2
Diazepam
(2 mg/kg)		74.0 ± 8.7 **336.0 ± 8.1 **24.0 ± 8.2 **
* indicates p ≤ 0.05 at the probability level; ** denotes differences that are statistically significant compared with the control.
Table
Table 8. Characterization of the parameters of amnestic functions on the model of electroshock retrograde amnesia after administration of hybrid compounds 7a, d, g, i, j, m, and n (study for 5 min).
Table 8. Characterization of the parameters of amnestic functions on the model of electroshock retrograde amnesia after administration of hybrid compounds 7a, d, g, i, j, m, and n (study for 5 min).
Compound,
Dose 50 mg/kg		The Time Spent in the Light Chamber during the Training of the CRPA (s), First DayThe Time Spent in the Light Chamber When Playing CRPA + MESH after 24 h, Second Day
Control280.0 ± 7.5281.0 ± 6.1
7a286.0 ± 4.3298.0 ± 6.9 **
7d284.0 ± 6.8299.0 ± 7.2 **
7g283.0 ± 5.2297.0 ± 7.2 **
7i286.0 ± 6.3299.0 ± 6.3 **
7j293.0 ± 7.2120.0 ± 5.8 **
7m282.0 ± 6.8296.0 ± 5.4 **
7n283.0 ± 7.1297.0 ± 6.8 **
Diazepam,
(2 mg/kg)		187.0 ± 6.7 *126.0 ± 6.5 **
Piracetam
(1000 mg/kg)		158.0 ± 5.9 *243.7 ± 8.4 **
Notes. CRPA + MESh—conditioned reaction of passive avoidance + maximal electric shock; *—significantly different from intact control without MES; **—significantly different from the control with MES, at p ≤ 0.05.
Table
Table 9. Molecular docking free binding energies (kcal/mol) into the GABAA receptor (PDB code: 4COF).
Table 9. Molecular docking free binding energies (kcal/mol) into the GABAA receptor (PDB code: 4COF).
NoEst. Binding Energy
(kcal/mol)		I–HResidues Involved in Hydrogen Bond FormationHydrophobic
Interactions		Aromatic Interactions
7a−8.512Thr202 (N···H, 2.64Å), Tyr205 (N···H, 2.77Å)Ala25, Tyr62, Leu99, Phe200Phe200
7d−7.101Thr202 (N···H, 3.26Å)Tyr62, Leu99, Phe200-
7g−7.901Thr202 (N···H, 3.30Å)Thr176, Phe200, Ala201-
7j−10.363Tyr97 (N···H, 3.31Å), Thr202 (N···H, 3.13Å), Tyr205 (N···H, 2.95Å)Thr176, Ala201, Phe200-
7m−7.20--Ty157, Tyr205-
Diazepam−8.901Thr202 (N···H, 2.67Å)Tyr62, Thr176, Phe200, Ala201, Tyr205Phe200
Table
Table 10. Molecular docking free binding energies (kcal/mol) in the SERT transporter (PDB ID: 3F3A).
Table 10. Molecular docking free binding energies (kcal/mol) in the SERT transporter (PDB ID: 3F3A).
NoEst. Binding Energy
(kcal/mol)		I–HResidues Involved in Hydrogen Bond FormationResidues Involved in Hydrophobic
Interactions		Residues Involved in Aromatic
Interactions
7a−9.923Arg11 (N···H, 2.53Å),
Lys443 (N···H, 2.42Å),		--
7d−7.101Arg7 (N···H, 2.62Å),Gly432, Gly433, Lys436Lys264
7g−5.24--Arg7, Arg431-
7j−7.231Gln266 (N···H, 2.74Å),Asp267, Gly432, Gly433-
7m−6.951Arg7 (N···H, 3.23Å),Asp267, Gly433Lys264
Table
Table 11. Molecular docking free binding energies (kcal/mol) in the 5-HT1A receptor (PDB ID: 3NYA).
Table 11. Molecular docking free binding energies (kcal/mol) in the 5-HT1A receptor (PDB ID: 3NYA).
NoEst. Binding Energy
(kcal/mol)		I–HResidues Involved in Hydrogen Bond FormationResidues Involved in
Hydrophobic
Interactions
7a−11.235Tyr118 (O···H, 2.73Å), Tyr199 (N···H, 2.64Å), Ser204 (N···H, 3.54Å), Asn312 (N···H, 3.17Å), Tyr316 (N···H, 3.76 Å)Trp109, Ile309, Tyr308, Phe193, Val114, Tyr110, Ile201, Val297, Ala200
7d−7.241Tyr308 (N···H, 3.88Å)Trp286, Asn312
7g−8.271Asn312 (N···H, 2.82Å)Phe108, Tyr308
7j−9.221Tyr316 (N···H, 2.59Å)Thr118, Ala200, Asn312
7m−5.60--Ser207, Phe108, Asn312
Alprenolol−13.194Asp113, Asn312, Tyr316Tyr118, Ala200, Tyr308
Table
Table 12. Absorption and distribution profiles and drug-likeness scores of all tested compounds.
Table 12. Absorption and distribution profiles and drug-likeness scores of all tested compounds.
NoAbsorptionDistributionDrug-Likeness Model Score
Human Intestinal Absorption (HIA)Human Oral Bioavailability (HOB)Caco-2 PermeabilityPlasma Protein Binding (PPB)P-Glycoprotein Inhibitor, SubstrateBlood-Brain Barrier Penetration (BBB)
7a(+) 0.99(−) 0.62(−) 0.810.63(+) 0.74, (+) 0.71(+) 0.820.83
7b(+) 0.99(−) 0.63(−) 0.820.57(+) 0.75, (+) 0.72(+) 0.820.67
7c(+) 0.99(−) 0.64(−) 0.820.55(+) 0.75, (+) 0.71(+) 0.800.65
7d(+) 0.99(−) 0.55(−) 0.820.55(+) 0.75, (+) 0.65(+) 0.770.51
7e(+) 0.99(−) 0.55(−) 0.820.56(+) 0.75, (+) 0.70(+) 0.820.66
7f(+) 0.99(−) 0.61(−) 0.820.57(+) 0.75, (+) 0.73(+) 0.820.80
7g(+) 0.99(−) 0.64(−) 0.820.56(+) 0.75, (+) 0.71(+) 0.820.80
7h(+) 0.99(−) 0.62(−) 0.820.53(+) 0.75, (+) 0.73(+) 0.820.65
7i(+) 0.99(−) 0.64(−) 0.820.50(+) 0.74, (+) 0.71(+) 0.800.63
7j(+) 0.99(−) 0.57(−) 0.830.75(+) 0.78, (+) 0.70(+) 0.770.64
7k(+) 0.99(−) 0.57(−) 0.830.74(+) 0.78, (+) 0.73(+) 0.800.65
7l(+) 0.99(−) 0.61(−) 0.830.72(+) 0.78, (+) 0.76(+) 0.800.78
7m(+) 0.99(−) 0.58(−) 0.820.54(+) 0.75, (+) 0.61(+) 0.770.35
7n(+) 0.99(−) 0.58(−) 0.830.54(+) 0.75, (+) 0.68(+) 0.800.51
7o(+) 0.99(−) 0.62(−) 0.830.63(+) 0.75, (+) 0.71(+) 0.800.66
7p(+) 0.99(−) 0.58(−) 0.830.56(+) 0.75, (+) 0.67(+) 0.800.51
7q(+) 0.99(−) 0.60(−) 0.830.58(+) 0.75, (+) 0.66(+) 0.800.33
7r(+) 0.99(−) 0.62(−) 0.830.62(+) 0.75, (+) 0.72(+) 0.800.50
7s(+) 0.99(−) 0.62(−) 0.830.66(+) 0.75, (+) 0.70(+) 0.800.66
7t(+) 0.99(−) 0.62(−) 0.830.64(+) 0.75, (+) 0.72(+) 0.800.50
7u(+) 0.99(−) 0.64(−) 0.830.61(+) 0.75, (+) 0.70(+) 0.800.47
The numbers in the table represent the % of probability.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sirakanyan, S.N.; Spinelli, D.; Petrou, A.; Geronikaki, A.; Kartsev, V.G.; Hakobyan, E.K.; Yegoryan, H.A.; Zuppiroli, L.; Zuppiroli, R.; Ayvazyan, A.G.; et al. New Bicyclic Pyridine-Based Hybrids Linked to the 1,2,3-Triazole Unit: Synthesis via Click Reaction and Evaluation of Neurotropic Activity and Molecular Docking. Molecules 2023, 28, 921. https://doi.org/10.3390/molecules28030921

AMA Style

Sirakanyan SN, Spinelli D, Petrou A, Geronikaki A, Kartsev VG, Hakobyan EK, Yegoryan HA, Zuppiroli L, Zuppiroli R, Ayvazyan AG, et al. New Bicyclic Pyridine-Based Hybrids Linked to the 1,2,3-Triazole Unit: Synthesis via Click Reaction and Evaluation of Neurotropic Activity and Molecular Docking. Molecules. 2023; 28(3):921. https://doi.org/10.3390/molecules28030921

Chicago/Turabian Style

Sirakanyan, Samvel N., Domenico Spinelli, Anthi Petrou, Athina Geronikaki, Victor G. Kartsev, Elmira K. Hakobyan, Hasmik A. Yegoryan, Luca Zuppiroli, Riccardo Zuppiroli, Armen G. Ayvazyan, and et al. 2023. "New Bicyclic Pyridine-Based Hybrids Linked to the 1,2,3-Triazole Unit: Synthesis via Click Reaction and Evaluation of Neurotropic Activity and Molecular Docking" Molecules 28, no. 3: 921. https://doi.org/10.3390/molecules28030921

Article Metrics

Back to TopTop